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Abstract 
 
Obesity poses a major health problem since it increases the risk for type 2 
diabetes, metabolic syndrome, heart disease, and cancer. Mutations in SH2B1 have 
been identified in patients exhibiting severe childhood obesity and insulin resistance. 
Mice deficient in SH2B1 exhibit a similar phenotype to the patients, suggesting an 
important role for SH2B1 in regulating energy homeostasis. SH2B1 is alternatively 
spliced, leading to four isoforms (alpha, beta, gamma, and delta) that share an N-
terminal 631 amino acids but have unique C-terminal tails. The findings that all SH2B1 
isoforms are expressed in the brain and neuronal expression of SH2B1 beta rescues 
the obese phenotype in SH2B1-deficient mice suggest that SH2B1 plays an important 
function in neurons. In further support of a neuronal function for SH2B1, SH2B1 
enhances neurotrophic factor-induced neurite outgrowth and the human obesity-
associated mutations impair the ability of SH2B1 to promote neurite outgrowth.  To gain 
insight into critical functions of SH2B1, its isoforms, and the human obesity-associated 
mutations, the work in this thesis characterizes the ability of rare SH2B1 mutations 
associated with human obesity both shared by all isoforms and those specific to SH2B1 
alpha to affect cellular actions of SH2B1.  It further examines how the unique C-terminal 
tails of SH2B1 regulate the actions of the shared 631 N-terminal amino acids of SH2B1. 
Our collaborator I. S. Farooqi identified variants in SH2B1 encoding for R227C, 
G238C, R270W, E299G, or T546A and the SH2B1 alpha-specific mutations A663V, 
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V695M, or A723V in individuals with severe-early onset obesity and insulin resistance. 
We determined that like SH2B1 beta, SH2B1 alpha enhanced growth hormone-
stimulated motility of macrophages and the mutations T546A, A663V and A723V 
impaired that enhancement. Unlike SH2B1 beta, SH2B1 alpha was unable to enhance 
NGF-mediated neurite outgrowth and the mutations in SH2B1 alpha had no impact. 
However, mutations G238C, R270W, E299G and T546A impaired SH2B1 beta-
enhancement of NGF-induced neurite outgrowth. This led us to conclude that variants 
can disrupt specific isoform function, suggesting novel regulatory roles in SH2B1 
isoform function. The discrepancy between SH2B1 alpha and beta regulation of neurite 
outgrowth directed us to ask how the unique C-terminal tails of the alpha and beta 
isoforms affect the ability of SH2B1 to regulate NGF-induced neurite outgrowth. By 
comparing the actions of SH2B1 alpha and beta to those of the N-terminal 631 amino 
acids shared by all isoforms of SH2B1, we found that the alpha tail prevents: 1) the 
ability of SH2B1 to cycle through the nucleus, and 2) SH2B1 enhancement of NGF-
induced neurite outgrowth, gene expression, and phosphorylation of NGF-receptor, 
TrkA, and downstream signaling proteins Akt and PLC gamma. These functions were 
restored when Tyr753 in the alpha tail was mutated to Phe, suggesting that 
phosphorylation of Tyr753 regulates SH2B1 alpha function. We provide evidence that 
TrkA phosphorylates Tyr55 and Tyr439 in both SH2B1 alpha and SH2B1 beta, and 
Tyr753 in SH2B1 alpha. Finally, co-expression of SH2B1 alpha inhibits the ability of 
SH2B1 beta to enhance NGF-induced neurite outgrowth.  These results suggest that 
the C-terminal tails of SH2B1 isoforms are key determinants of their cellular roles and 
are regulated by phosphorylation. By providing valuable information about how 
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seemingly minor differences between isoforms can have a profound impact on the 
function of that protein, my studies also provide important insight into the impact of 
differential splicing on neuron function. 
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Chapter 1 
 
 
Introduction 
 
Chromosomal deletions and variants within SH2B1 promote obesity 
 
Obesity affects an ever-growing and alarming percentage of adults in developed 
countries. The prevalence of obesity in the United States is high, with 35% of adults and 
17% of youth (ages 2 through 19) considered obese (1). Obesity poses a major health 
problem since it increases the risk for such diseases as type 2 diabetes, metabolic 
syndrome, heart disease, and cancer. Obesity has been described as an imbalance of 
energy intake to energy output. According to the Centers for Disease Control, this 
imbalance results from many factors including environmental, social, behavioral, and 
physiological factors, mental and physical disabilities, drugs and genetic predisposition. 
Thus, insight into novel factors that regulate human obesity are of obvious health 
relevance. The gene encoding the scaffolding protein SH2B1 (SH2-B; PSM) is one such 
novel factor.  
SH2B1 encodes for the scaffold protein SH2B1, a member of a family of SH2 
domain-containing scaffold proteins along with SH2B2 (APS) and SH2B3 (LNK), all of 
which bind to phosphotyrosines in specific receptor tyrosine kinases (RTKs) and 
cytokine receptor-associated JAK kinases. SH2B1 is composed of 10 exons; four 
SH2B1 isoforms (α, β, γ, δ) are generated through alternative splicing by utilization of 
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two splice sites in exon 8 and exon skipping or inclusion of exon 9. The four isoforms 
share an N-terminal region but have unique C-terminal tails that diverge after the SH2 
domain and differ in both amino acid sequence and length (Figure 1.1) (2-5). The 
isoforms have been shown to be expressed in pairs of α and δ or β and γ, in both 
rodents and human (2,6).  All four isoforms of SH2B1 are expressed in the human brain; 
the ubiquitously expressed β and γ isoforms are also expressed in non-neuronal tissues 
(6).  All four isoforms of SH2B1 contain several proline-rich domains, a phenylalanine 
zipper dimerization domain, a nuclear localization signal and nuclear export signal, a 
pleckstrin homology (PH) domain and a Src homology 2 (SH2) domain (Figure 1.1).  
Variants at loci in or near SH2B1 have been associated with obesity based on 
genomic wide association studies (GWAS) (7-9).  These studies using a cohort with 
obese individuals from primarily European descent identified variants at or near a region 
containing the SH2B1 locus and other genes. SH2B1 and the other genes are 
expressed in the brain, including the hypothalamus (7). In the central nervous system 
(CNS), the hypothalamus regulates food intake and energy homeostasis. Several more 
GWASs have recapitulated these results in non-European populations to further 
establish that these variants at or near loci containing SH2B1 are associated with 
obesity (10,11).  Individuals with deletions of a region at chromosome 16p11.2 that 
encompass the SH2B1 locus exhibit severe early-onset obesity (12-15).  They also 
exhibit severe insulin resistance that is disproportionate for the degree of obesity, and 
developmental delay (12-15). Our collaborator, I. Sadaf Farooqi (University of 
Cambridge) has now identified more than 20 patients with mutations in SH2B1 in a  
cohort of patients from the Genetics of Obesity Study (GOOS) that exhibit severe early- 
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Figure 1.1. Schematic of the four human SH2B1 isoforms. Shown are the proline-
rich regions (P), dimerization domain (DD), nuclear localization signal (NLS), nuclear 
export signal (NES), pleckstrin homology domain (PH), Src-homology 2 domain (SH2), 
and tyrosine sites (Y). Unique C-terminal tails are depicted in color. 
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onset childhood obesity and insulin resistance (6). 
The GOOS was established in 1997 to determine how individuals at an early age 
(<10 years old) gain weight. Since most children are not pathologically obese prior to 10 
years of age, studying obesity at an early age enhances the ability to identify individuals 
with a genetic predisposition to obesity. As of 2002, the consortium had recruited over 
4300 severely obese children to the obesity study and discovered mutations that disrupt 
the leptin neuro-endocrine signaling pathway in 8% of their cohort (16). To determine 
whether SH2B1 variants associate with severe-early onset obesity, our collaborator, I. 
Sadaaf Farooqi selected from the GOOS, a cohort of 300 obese children (≤ 10 years 
old) with a phenotype similar to that of the 16p11.2 gene deletion patients (BMI SDS of 
≥ 3, and disproportionate degree of insulin resistance as defined by the presence of 
type 2 diabetes and/or markedly elevated plasma insulin levels) and screened them for 
mutations in SH2B1. Four non-synonymous mutations were identified in SH2B1 codons 
encoding for amino acids P90, T175, P322, and F344 (6). Three of the mutations 
caused single amino acid changes (P90H, T175N, P322S) and the fourth mutation 
caused a frame shift and premature termination before the SH2 domain (F344LfsX20) 
(6). Carriers were all hyperphagic, and when both phenotype and genotype information 
of family members were available, mutations were usually found to be inherited from 
overweight/obese parents. Surprisingly, these identified patients, but not the parents, 
exhibited maladaptive behavior (social isolation, aggression). Studies using a different 
cohort of obese patients (17), identified a rare variant associated with obesity in children 
and adolescents in exon 9 of SH2B1, an exon only present in the β and γ isoforms of 
SH2B1 (Figure 1.2). This non-synonymous mutation changed Thr656 to Ile in SH2B1β 
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and Pro674 to Ser in SH2B1γ (17).  Taken together, the GWAS, gene deletion and rare 
variant data suggest that SH2B1 helps protect against obesity.  As described in Chapter 
2, additional mutations have been identified in the unique C-terminal tails of SH2B1 
(Figure 1.2).  
Mice lacking SH2B1 (Sh2b1-/-) have a similar phenotype to that seen in humans 
with mutations in SH2B1 or chromosomal deletions encompassing SH2B1.  Sh2b1-/- 
mice, on either a 129Sv/C57BL/6 or C57BL/6 background, weighed significantly more 
than their wild-type (WT) littermate controls after 10 weeks of age when fed a 9% fat 
standard chow (18). Sh2b1-/- mice exhibited hyperphagia, hyperleptinemia, insulin 
resistance and hyperglycemia (18,19). However, using a different group of Sh2b1-/- mice 
on a 129sv/C57BL/6 background Ohtsuka, et al. (20) reported no obesity in their Sh2b1-
/- mice assessed at 4- and 6- weeks of age. This apparent discrepancy may be due to 
the age at which the Ohtsuka group assessed body weight, since the Rui lab found that 
Sh2b1-/- mice has normal weight at less than 6 weeks of age and further analysis 
revealed weight gain after 10 weeks of age in their Sh2b1-/- mice.  These studies, in 
mice, show that SH2B1 is an important regulator of body weight in mice.  
In addition to obesity, Sh2b1-/- mice exhibit behavioral and reproductive 
phenotypes.  Like humans with mutations in SH2B1, male Sh2b1-/- mice are aggressive 
toward their littermates and animal handlers (L. Rui, University of Michigan; personal 
communication).  Both male and female Sh2b1-/- mice also have impaired fertility 
exhibited by the lower than normal Mendelian ratio of Sh2b1-/- intercrosses (19,20). The 
impaired fertility in Sh2b1-/- females was attributed to small ovaries with reduces follicle 
numbers and small testes with low sperm number in Sh2b1-/- males (20). These 
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Figure 1.2. Schematic of SH2B1 isoforms and obesity-associated mutations 
identified in humans.  P= Proline-rich region, DD = Dimerization Domain, NLS = 
Nuclear Localization Sequence, NES = Nuclear Export Sequence. Numbers = amino 
acids. The obesity-associated mutations are indicated. The T656I (*) mutations in the 
SH2B1β isoform and the P674S mutation in the SH2B1γ isoform originate from the 
same nucleotide variant. 
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additional phenotypes suggest that the role of SH2B1 extends beyond the regulation of 
energy homeostasis.  
Collectively, these results in humans and mice suggest that SH2B1 is an 
important regulator of energy balance, insulin and leptin sensitivity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 
 
 
 
The scaffold protein SH2B1 is implicated in metabolic and neuronal cell signaling 
 
Cells respond to an environmental stimulus through cellular signaling pathways 
to attain a precise and suitable response.  An extracellular signaling factor (e.g. 
hormone, growth factor) mediates signaling outputs within the cell by interacting with its 
receptor located in the cell’s plasma membrane. These receptors include ligand-gated 
ion channels, G-protein coupled receptors, and protein kinase receptors, including 
receptor tyrosine kinases. In the case of receptor tyrosine kinases, signaling events are 
initiated by ligand to binding its receptor tyrosine kinase resulting in a conformational 
change which activates the kinase, thereby causing the kinase to auto-phosphorylate.  
The resulting phosphorylated tyrosines recruit proteins, including scaffold proteins, that 
contain SH2 or other phosphotyrosine binding domains to create a signaling complex 
that mediates downstream signaling. These signaling complexes mediate a variety of 
cellular responses, including an appropriate transcriptional response (21). Scaffold 
proteins, despite lacking enzymatic activity, can serve to recruit a unique multiprotein 
complex, therefore helping to create a diverse and individual response for a specific 
signal.  
 SH2B1 interacts with activated receptor tyrosine kinases through its SH2 domain 
to modulate signaling. Isoforms of SH2B1 have been found to interact with 
phosphorylated tyrosines in receptors for insulin (3,22), insulin-like growth factor (IGF-1) 
(23), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF) (24), nerve 
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growth factor (NGF) (25,26), brain-derived neurotrophic factor (BDNF) (25,27), and 
glial-derived neurotrophic factor (GDNF) (28). In addition, SH2B1β was found to interact 
with multiple members of the Jak family of tyrosine kinases (Jaks 1, 2, and 3) (4,29,30). 
Jak kinases associate with members of the cytokine family of receptors and are 
activated by ligand binding to these receptors.  Like SH2B1β, several of these receptors 
play critical roles in metabolism and energy expenditure, suggesting the importance of 
understanding how SH2B1 impacts their function. 
 
The role of SH2B1 in leptin signaling 
 Leptin is an adipose tissue-derived hormone that regulates energy homeostasis 
by interacting with leptin receptor-containing neurons within the arcuate nucleus of the 
hypothalamus to decrease food intake (31,32). Humans with mutations in leptin and 
leptin-deficient mice are extremely obese due to their hyperphagia (33,34). In mice, 
mutations in the long form of the leptin receptor (LepRb) or deletion of the leptin 
receptor also result in severe obesity and hyperphagia (35,36). These phenotypes are 
similar to those found in humans with haploinsufficiency of, or point mutation, in SH2B1 
and Sh2b1-/- mice.  as previously discussed in section I of the introduction. SH2B1 is 
thought to enhance leptin signaling through its interaction with the leptin receptor-
associated kinase, Jak2 (18,37-39). Leptin binding to LepRb activates Jak2, which 
phosphorylates LepRb on tyrosines 985, 1107, and 1138 (39). PhosphoTyr985 on 
LepRb has been implicated as a binding site for SHP2 (40) and/or SOCS3. 
PhosphoTyr1138 on LepRb recruits the transcription factor STAT3 (signal transducer 
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and activator of transcription 3) (39,40). In response to leptin, Jak2 autophosphorylation 
of Tyr1007 activates Jak2 (41). Phosphorylation of Tyr317 (42) and Tyr570 (43) inhibit 
Jak2 activity and Tyr637 stimulates Jak2 activity (42). In addition, Tyr221 on Jak2 is 
phosphorylated in response to leptin but a function for Tyr221 in leptin function has yet 
to be determined (44 ). Auto-phosphorylation of Jak2-Tyr813 has been reported to 
recruit SH2B1 via its SH2 domain, and enhance the activity of Jak2 (37). In addition, 
insulin receptor substrates (IRS) 1 and 2 are recruited to the LepRb-Jak2-SH2B1 
complex where they are phosphorylated by Jak2 and in turn recruit and activate 
phosphatidylinositol 3-kinase (PI3K), leading to activation of signaling pathways 
downstream of PI3K (37,45). Consistent with these in vitro results, Sh2b1-/- mice are 
leptin resistant (18) and when wild-type and Sh2b1-/- mice are administered leptin, 
Sh2b1-/- mice display decreased tyrosine phosphorylation of hypothalamic IRS1 (18). 
These data suggest that SH2B1 is a critical signaling molecule for and positive regulator 
of leptin signaling.  
 
The role of SH2B1 in insulin signaling 
 In addition to leptin signaling, SH2B1 has been shown to play a role in insulin 
signaling. Mouse models lacking Sh2b1 have shown impaired insulin receptor activation 
and signaling in liver, skeletal muscle, and adipose tissue (19,46). This impaired 
signaling is thought to contribute to the hyperinsulinemia, hyperglycemia, and glucose 
intolerance seen in the Sh2b1-/- mice (19,46). SH2B1α and β isoforms have been shown 
to associate through their SH2 domain with phosphotyrosines within the kinase 
activation loop (Tyr1158, Tyr1162, Tyr1163) of the insulin receptor (3,47). In 293 cells, 
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co-expression of SH2B1β with insulin receptor enhances tyrosine phosphorylation of 
IRS1 and IRS2. While co-expression of SH2B1β R555E, which has a defective SH2 
domain, with insulin receptor, shows reduced tyrosine phosphorylation of IRS1 and 
IRS2 (45). In addition, decreased insulin-induced Akt phosphorylation in liver and 
muscle from Sh2b1-/- mice and reduced insulin-stimulated phosphorylation of ERKs 1 
and 2 in brown fat from Sh2b1-/- mice suggested that deletion of SH2B1 impairs the 
ability of insulin to stimulate phosphorylation of downstream signaling proteins (19). In 
addition, SH2B1 protects IRS1 from dephosphorylation by the tyrosine phosphatase 
PTP1B, suggesting SH2B1 may block the ability of IRS1 to interact with tyrosine 
phosphatases and thereby enhance and prolong tyrosyl-phosphorylation of IRS1 (48). 
Together these data suggest SH2B1 plays a significant role in insulin receptor activation 
and signaling important for glucose homeostasis.   
Despite these studies, the role of SH2B1 in insulin signaling in the brain has yet 
to be explored.  Several studies have shown insulin receptor expression in the 
hypothalamus, cerebral cortex, cerebellum, and hippocampus, which are regions of the 
brain associated with energy homeostasis and behavior (49,50).  Administration of 
higher than physiological levels of insulin directly to the brain results in an inhibition of 
food intake and decreased body weight, whereas inhibition of insulin signaling increases 
food intake, resulting in higher body weight (51-53). These data suggest insulin 
signaling in the brain has a unique role in regulating energy homeostasis. Restoration 
SH2B1β expression in neurons in transgenic Sh2b1-/-  mouse models largely rescued 
the insulin resistance, glucose intolerance and reduced tissue adiposity in Sh2b1-/- mice 
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(54), suggesting SH2B1 plays a critical role in neuronal insulin signaling regulating 
glucose homeostasis. 
 
Effects of human obesity-associated mutations in SH2B1 on leptin and insulin 
signaling 
It has yet to be determined how the human obesity-associated mutations in 
SH2B1 affect leptin and insulin signaling. The Carter-Su laboratory has found that 
introducing mutations associated with human obesity (P90H, A175N, and P322S) into 
SH2B1β did not alter SH2B1β enhancement of Jak2 activity when both were transiently 
expressed in 293T cells; nor did the mutations alter SH2B1β enhancement of leptin-
induced phosphorylation of IRS2 in 293 cells stably expressing LepRb and transiently 
expressing IRS2 and SH2B1β (WT or mutant) (6). Similar results were reported for 
insulin-induced phosphorylation of IRS2 in 293 cells transiently overexpressing the 
various forms of SH2B1 and IRS2 (6). However, the artificially high level of expression 
of SH2B1 and IRS2 in the transfected 293 cells may have concealed any impairments 
induced by SH2B1 human obesity-associated mutations enhancement. Volckmar, et al. 
(17) similarly determined that the obesity variants T656I in SH2B1β and P674S in 
SH2B1γ had no effect on the ability of the respective SH2B1 isoforms to stimulate 
leptin-mediated activation of STAT3. Collectively, these data suggest that SH2B1 is a 
positive regulator of leptin signaling and that subtle impairments by SH2B1 human 
obesity-associated variants need to be further examined under more physiological 
conditions or in different assays. 
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The role of SH2B1 in neurotrophic factor signaling 
In addition to its role in leptin and insulin signaling, the role of SH2B1 in 
mediating signal transduction pathways for several neurotrophic factors has been 
investigated.  Nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and 
neurotrophin-3 (NT-3) bind to their receptor tyrosine kinases TrkA, TrkB, and TrkC, 
respectively (55,56). Neurotrophic factors are critical for the differentiation and survival 
of developing neurons in the central and peripheral nervous systems (57). NGF binding 
to TrkA activates TrkA and causes TrkA auto-phosphorylation of tyrosines in both the 
kinase (Tyr670, Tyr674, and Tyr675) and non-kinase (Tyr490 and Tyr785) domains (58-
60).  Most studies looking at the effects of SH2B1 on neurotrophic factor signaling have 
been carried out in the rat adrenal pheochromocytoma cells (PC12), which have 
endogenous expression of TrkA and extend neurites in response to NGF (61,62). In 
response to NGF, SH2B1 has been shown to interact via its SH2 domain with 
phosphorylated tyrosines within the kinase domain of TrkA (25). The exact tyrosine 
responsible for recruiting SH2B1 remains to be determined. Overexpression of SH2B1α 
enhances NGF-mediated tyrosine phosphorylation of Tyr490 in TrkA (63). Activation of 
TrkA in PC12 cells also results in phosphorylation of SH2B1 on tyrosines as well as 
serines and threonines suggesting that kinases, like ERK1 and ERK2, or other 
downstream kinases are important for NGF-stimulated neurite extension (64). 
Prolonged phosphorylation of ERK1 and ERK2, is critical for NGF-mediated neurite 
outgrowth (65-67).  Overexpression of SH2B1α(25) or SH2B1β (26) enhances NGF-
induced neurite outgrowth in PC12 cells suggesting that SH2B1 may enhance energy 
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balance at least in part by enhancing formation of the neuronal circuits involved in 
feeding behavior.  
NGF-mediated activation of TrkA and recruitment of SH2B1 presumably 
promotes the recruitment of signaling molecules that elicit or regulate downstream 
signaling pathways that regulate neurite extension. Induction of NGF-mediated neurites 
in PC12 cells requires prolonged phosphorylation of TrkA and its downstream signaling 
proteins, especially ERK1 and 2 (65-67).  Qian et al showed that the adapter protein, 
Grb2, interacts with SHB21α under non-NGF and NGF conditions. Grb2 is implicated in 
the regulation of ERK 1 and ERK2 (68). In 293 cells, transient co-expression of TrkA 
and truncated versions of SH2B1α identified a Grb2 binding domain within a proline-rich 
region between amino acids 384-504 (25). To determine whether the proline-rich region 
of SH2B1α is necessary for enhancing MAPK activity, 293 cells transiently expressing 
TrkA, HA-ERK1, and SH2B1α WT or SH2B1α without the Grb2 interacting region were 
tested for NGF-mediated ERK1 activity. NGF-mediated ERK1 activity was increased by 
SH2B1α WT and to a lesser extent by the truncated SH2B1α suggesting that 
constitutive binding of SH2B1α with Grb2 enhances ERK1 activity (25).  These data 
suggest SH2B1 interacts with at least one other adaptor protein (i.e. Grb2) to enhance 
neurotrophic signaling necessary for neurite extension. However, not all research labs 
have found that SH2B1 isoforms that enhance neurite extension enhance ERK1 and 
ERK2 activity.  
The Carter-Su lab has not found SH2B1β to reproducibly enhance NGF-
activation of ERK1 and ERK2 (26,69). The Carter-Su lab has, however, identified other 
NGF signaling pathways that may contribute to SH2B1-enhancement of NGF-induced 
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neurite extension.  NGF-induced phosphorylation of ERK1 and ERK2 was not enhanced 
in PC12 cells overexpressing SH2B1β, or decreased in cells either overexpressing the 
dominant negative SH2B1β R555E, or in which SH2B1 levels were reduced using 
shRNA (26,69). They found that stable overexpression of SH2B1β, but not SH2B1β 
R555E,  in PC12 cells enhances and prolongs NGF-dependent phosphorylation of Akt, 
GSK3α/β, and FOXO3 in an NGF-dependent manner (70). The PI3K/Akt has been 
shown to be required for NGF-mediated sympathetic neuron survival (71). However, 
surprisingly, reducing endogenous levels of SH2B1 by 50-70% using shRNA did not 
reduce NGF-induced phosphorylation of Akt (69). Taken together, these data suggest 
that SH2B1β and SH2B1α can modulate NGF signaling pathways implicated in 
neuronal differentiation and survival. However, it is unclear how the dominant negative 
SH2B1 R555E or knockdown of SH2B1 impairs enhanced NGF-mediated neurite 
outgrowth without altering NGF-induced activation of ERK1 and ERK2 suggesting 
SH2B1 may impact NGF-signaling pathways yet to be identified. 
The interaction of SH2B1 with the BDNF receptor tyrosine kinase, TrkB, has also 
been studied. Like Sh2b1-/- mice, disruption of BDNF or TrkB in mice has been shown to 
induce hyperphagia and obesity (72-74) suggesting that the TrkB-SH2B1 interaction 
may be important for the effects of SH2B1 on energy balance. SH2B1 was found to 
interact with TrkB in a yeast-two hybrid screen used to identify TrkB substrates in dorsal 
root ganglia (25). Shih et al. provided further validation of the BDNF-mediated 
interaction between SH2B1β and TrkB in a 293T cell overexpression system (27). Like 
TrkA, TrkB tyrosyl phosphorylates SH2B1 isoforms in vitro and in cultured cortical 
neurons (25,27).  Transient overexpression of SH2B1β in cultured primary hippocampal 
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neurons enhanced BDNF-induced neurite length and branching (27). In addition, Shih et 
al. showed reduced BDNF-induced neurite length and branching using shRNA to 
knockdown SH2B1 in cultured primary cortical neurons (27). In PC12 cells stably 
overexpressing TrkB and SH2B1β, BDNF-mediated neurite-outgrowth and 
phosphorylation of downstream signaling proteins PLCγ, STAT3, ERK1/2, and Akt was 
enhanced and prolonged compared to TrkB expressing cells (75). Collectively, these ex 
vivo and in vitro experiments suggest SH2B1 is an important mediator of BDNF 
signaling leading to BDNF-induced neurite extension. 
 Together, the demonstration that SH2B1 enhances neurotrophic factor induced 
neurite outgrowths and signaling pathways indicate that it is critical to understand the 
function of SH2B1 in neurons. In support of this, SH2B1 has been implicated in 
neurotrophin-induced neurite outgrowth of several different neurons yet the mechanism 
by which SH2B1 regulates neurite outgrowth and branching remains unclear. Also, it is 
unclear whether SH2B1 enhanced neurite outgrowth is critical for maintaining energy 
homeostasis.  
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Characterizing the cellular and molecular functions of SH2B1 
 
 
Subcellular localization of SH2B1 
In this section, I will summarize critical data performed by our laboratory and 
others concerning the subcellular localization of SH2B1.  Domains and post-
translational modifications in unique regions of SH2B1 play a critical role in regulating 
the cellular localization of SH2B1. Some of the roles of SH2B1β in response to NGF are 
illustrated in the model shown in Figure 1.3. The dimerization, NLS, NES, and SH2 
domains and post-translational modifications within the N-terminal 630 amino acids 
dictate where SH2B1 localizes within the cell. N-terminal GFP-tagged SH2B1β has 
been shown to localize on the plasma membrane and the cytoplasm (26,69,76). GFP-
tagged SH2B1β is not visible in the nucleus by confocal microscopy under steady state 
conditions in 293T, COS-7, and PC12 cells (69,76). Truncation mutants of GFP-tagged 
SH2B1 that lack the NES (GERWTHRFERL231RL233SR), mutation of the NES, or 
inhibition of the nuclear exportin protein, Crm1, with leptomycin B (LMB) leads to an 
accumulation of SH2B1β in the nucleus (76) indicating that SH2B1β cycles in and out of 
the nucleus. The localization of the α, γ, and δ SH2B1 isoforms had yet to be 
determined at the start of this thesis. A putative NLS (KLK150KR) in SH2B1β was 
identified by sequence analysis (69) and point mutations within the NLS of SH2B1β 
prevented SH2B1β from accumulating in the nucleus even in the presence of LMB (69)  
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Figure 1.3. Model illustrating some of the many roles of SH2B1β in response to 
NGF.  SH2B1β is localized in the cytoplasm and on the plasma membrane and shuttles 
between the cytoplasm and nucleus. TrkA dimerizes in response to NGF stimulation to 
recruit SH2B1β and phosphorylate SH2B1β. The signaling complex mediates 
phosphorylation of downstream signaling proteins to elicit a nuclear response necessary 
neuronal differentiation.  In addition, SH2B1β binds to the actin and mediates 
cytoskeleton rearrangement necessary for neurite outgrowths and motility. 
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verified that this region functions as an NLS. SH2B1β was unable to enter the nucleus 
under ATP-depleted conditions, suggesting that nuclear localization of SH2B1β is 
energy dependent.  Intact NLS and NES motifs are required for SH2B1β to enhance 
NGF-mediated neurite outgrowth in PC12 cells (69,76). Mutations within the NLS or 
NES of SH2B1 which blocked nuclear entry or exit, respectively, had no effect on NGF-
mediated phosphorylation of TrkA or ERKs 1 and 2 (69,76). Furthermore, the dominant 
negative SH2B1 R555E mutant with a defective SH2 domain, which inhibits NGF-
induced neurite outgrowth, also fails to translocate to the nucleus but does not impair 
NGF-mediated ERK 1 and ERK2 phosphorylation (26) (69). These data suggest that 
nuclear translocation may be necessary for SH2B1 to enhance NGF-mediated neurite 
outgrowth. However, the role SH2B1 plays in the nucleus remains unknown. 
In addition to being observed in the cytoplasm and nucleus, SH2B1β has been 
observed at the plasma membrane. Some PH domains bring proteins to the plasma 
membrane through phosphatidylinositide interactions (77). Subcellular fractionation of 
cells expressing SH2B1 truncation mutants implicated the region encompassing the 
NLS and NES and not the PH domain for SH2B1β localization at the plasma membrane 
(78). To confirm the results of the subcellular fractionation assay, Maures et al. used 
confocal microscopy of live PC12 cells expressing GFP-tagged SH2B1β lacking amino 
acids 147-198 which encompasses the NLS to show a loss of SH2B1β on the plasma 
membrane (78).  Mutating the polybasic NLS itself also prevented SH2B1β from 
localizing at the plasma membrane suggesting that the NLS localizes SH2B1β to the 
nucleus and the plasma membrane through electrostatic interactions (78). To determine 
why the NLS is needed to recruit SH2B1β to both the nucleus and the plasma 
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membrane, Maures et al. (78) mutated all the serine residues adjacent to the polybasic 
NLS to alanines (13SA) and found that SH2B1β localized primarily on the plasma 
membrane.  By reducing the number of serine mutations in SH2B1β from 13SA to 2 
serine mutations adjacent to the NLS, it was determined that Ser161 and Ser165 were 
responsible for enhanced localization of SH2B1β at the plasma membrane in 293T and 
PC12 cells (78). Ser161 of SH2B1β was found to be phosphorylated by mass 
spectroscopy of phorbal ester treated PC12 cells, suggesting serines may be 
phosphorylated by protein kinase C (PKC) or another serine/threonine kinase (78).  In 
support of this, activation of PKC using phorbol esters caused SH2B1β to leave the 
plasma membrane and accumulate in the nucleus (78). However, while NLS was found 
to be necessary for plasma membrane localization of SH2B1b, it was not sufficient.  In 
addition, the dimerization domain was found to have a role in localizing SH2B1β to the 
plasma membrane (78). Mutating Ser154, Ser157, Ser161, and Ser165 to prevent their 
phosphorylation also reduced the ability of SH2B1β to enhance NGF-mediated 
expression of the early-response gene, Plaur (78). Collectively, these data concerning 
the plasma membrane localization of SH2B1 suggest that ligands that stimulate PKC or 
a PKC-like kinase cause Ser161 and Ser165 adjacent to the polybasic region of 
SH2B1β to be phosphorylated, thereby releasing SH2B1β from the plasma membrane 
and enabling it to enter the nucleus.  It unknown whether serine phosphorylation on α, γ, 
or δ SH2B1 isoforms similarly mediate the localization of SH2B1 to the plasma 
membrane.   
 
SH2B1 enhances transcriptional responses to NGF 
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To identify NGF- and SH2B1β-responsive genes that might play a role in 
SH2B1β promotion of NGF-induced neurite outgrowth, the Carter-Su laboratory 
performed microarray experiments using PC12 cells, or PC12 cells stably 
overexpressing SH2B1β or the dominant-negative SH2B1β R555E. Cells were treated 
for 6 hours with or without 100 ng/ml NGF (79). Subsequent microarray analysis 
revealed multiple NGF- and SH2B1β-regulated genes including plasminogen activator 
urokinase receptor (Plaur), and matrix metalloproteinases 3 and 10 (Mmp3, Mmp10) 
whose expression was substantially increased in cells expressing SH2B1β or 
decreased in cells expressing SH2B1β R555E, respectively. Plaur encodes urokinase 
plasminogen activator receptor, uPAR, which is located in the plasma membrane (79) 
and is required for NGF-mediated neurite outgrowth (80).  uPAR has also been 
implicated in such diverse cellular functions as cell migration and modulation of cyclic 
AMP(cAMP)/diacylglycerol (DAG)/calcium/inositol phosphate levels, which in turn affect 
many signaling molecules including PKC (81-83). uPAR, MMP3 and MMP10 are 
primary components of extracellular matrix degradation (ECM) pathways, which are 
necessary for cellular differentiation (i.e. pre-neuronal to neuronal) or motility (80,84-86). 
Inactive pro-urokinase plasminogen activator (pro-UPA) binds to uPAR and is activated 
by cathepsin cleavage.  The activated uPA can then cleave inactive plasminogen to 
form active plasmin enzyme which in turn cleaves pro-MMPs to form active MMPs (87).  
Northern blot analysis of Plaur transcripts from PC12 cells treated with epidermal 
growth factor (EGF) or NGF indicate that Plaur is induced to a much greater extent by 
NGF (80).  Knockdown of uPAR using antisense oligonucleotide to Plaur mRNA 
impeded PC12 NGF-mediated neurite differentiation (80). These results suggest that 
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nuclear SH2B1β may promote the expression of genes necessary for degrading the 
extracellular matrix to enable neurite extension. However, the mechanism by which 
SH2B1β promotes transcriptional changes in response to NGF is unknown. In addition, 
it is unknown whether SH2B1α, SH2B1γ, and SH2B1δ promote NGF-mediated 
enhancement of the same extracellular matrix degradation transcriptome as SH2B1β.  
 
The role of SH2B1 in cellular cytoskeleton rearrangement 
Neurite extension requires changes in the actin cytoskeleton. Therefore, it is not 
surprising that SH2B1β interacts with the cytoskeleton to help mediate ligand-induced 
changes to the cellular architecture (i.e. actin rearrangement). SH2B1β colocalizes with 
actin, and induces GH- and PDGF-mediated membrane ruffling and lamellipodia 
formation in 3T3-F442A fibroblasts (88).  Overexpression of SH2B1β WT enhanced, 
whereas the dominant-negative SH2B1β R555E impaired, GH-mediated membrane 
ruffling (88). SH2B1β was shown to binds to the small GTPase, Rac, in a GH-mediated 
fashion that requires amino acids 85-106 in SH2B1β (89). Membrane ruffles and 
lamellipodia formation have been shown to involve activated Rac (90).  Mutation studies 
revealed that post-translational modifications regulate SH2B1 functions critical for 
neurite extension and cellular motility. Mutation to Phe of SH2B1 Tyr439 and Tyr494, 
both YXXL sites shown to be substrates of GH-activated Jak2 (91,92), inhibited 
membrane ruffling in 3T3-F442A cells (91) and RAW macrophages (92) indicating 
tyrosine phosphorylation of SH2B1β regulates its ability to promote membrane ruffles. 
SH2B1β also localizes to focal adhesions (93).  Focal adhesions are integrin-based 
complexes that mediate the attachment interface between cells and the extracellular 
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matrix, mediate signaling between the extracellular matrix and cells as well as 
coordinate cell anchorage and motility (94). Phorbal esters stimulated release of 
SH2B1β from focal adhesions in fibroblasts (93). Mutation of Ser161 and Ser165, which 
prevents SH2B1β from dissociating from the plasma membrane, also blocked SH2B1 
release from focal adhesions (93). Mutating the NLS or introducing phosphomimetics to 
Ser161 and Ser165 in SH2B1β to reduce the ability of SH2B1 to bind the plasma 
membrane also enhanced GH-induced motility of RAW macrophages (92). These 
results show that SH2B1β is involved with actin rearrangement and focal adhesion 
dynamics that modulate the cellular architecture. The ability of SH2B1α, γ, and δ 
isoforms to modulate cellular ruffling and motility has yet to be examined.  
 In this thesis, I aimed to characterize the ability of the neuronal-specific isoform 
SH2B1α to shuttle through the nucleus, localize to the plasma membrane, modify NGF-
induced gene expression and promote both cell migration and neurite outgrowth.   
 
Effects of human obesity-associated mutations in SH2B1 on cellular motility and 
neurite extension 
 
The Carter-Su laboratory has characterized the effect of human obesity-
associated mutations in SH2B1 on cellular functions of SH2B1β. The human obesity-
associated mutations P90H, A175N, P322S, and F322LfsX20 impaired the ability of 
SH2B1β to shuttle through the nucleus (6). The F344LfsX20 mutation causes a frame 
shift resulting in a stop codon prior to the SH2 domain of SH2B1. Only the F322SLfsX20 
mutation in SH2B1β altered the plasma membrane localization of SH2B1 in 293T cells 
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(6). The loss of the SH2 domain due to the F344LfsX20 mutation, resulted in the loss of 
the ability of SH2B1 to enhance NGF-dependent PC12 neurite outgrowth and enhance 
GH-induced RAW macrophage mobility presumably due to an inability of SH2B1 to bind 
to NGF-receptor, TrkA, and GH receptor-associated kinase, Jak2 (6). Introducing the 
point mutations P90H, A175N, and P322S reduced the ability of SH2B1β to enhance 
both GH-mediated motility of macrophages and NGF-mediated neurite outgrowth in 
PC12 cells (6). In addition, the SH2B1 P322S mutation enhanced dimerization between 
SH2B1β P322S and SH2B1β WT (6). Because the human mutations are associated 
with obesity, these results suggest that the human mutations in SH2B1 might hinder the 
formation of the correct neuronal projections of neurons which regulate energy balance. 
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Alternative splicing of SH2B1 generates isoforms with unique C-terminal tails, 
enabling diversity in protein-protein interactions 
 
Changes in cellular morphology induced by growth factors require an appropriate 
cell signaling response that can elicit changes in the transcriptome and proteome.  
Sequencing of the human genome revealed 20,000 – 25,000 protein-coding genes (95). 
Approximately 92-95% of multi-exon genes have since been identified to undergo 
alternative splicing (96). Variation and regulation of transcript splicing events is more 
prevalent between tissues than amongst individuals (96).  These data suggest that 
alternative splicing of the human genome contributes to proteomic diversity and may 
facilitate the vast number of processes demanded by the phenotypic complexity of 
mammals.  The vast majority of spliced transcripts have been assocaited with key cell 
functions that include developmental processes, cell communication, signal 
transduction, regulation of metabolism, cell proliferation, and cell survival (96-98). 
Approximately 40% of genes expressed in the human brain are alternatively spliced, 
making the brain the tissue with the most alternative spliced events followed by the liver 
and testis (99-102). The expression of all four isoforms (α, β, γ, δ) of SH2B1 in the 
human brain (6) follow this trend. Therefore, the alternatively spliced transcripts of 
SH2B1 may function to modulate key complex cellular processes. Here I present 
background on the current research on alternative splicing of SH2B1 and the known 
roles of the unique C-terminal tails of SH2B1.  
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SH2B1 isoforms (α, β, γ, δ) are the products of a combination of exon skipping 
and alternative donor and acceptor splice sites (Figure 1.4).  The first 7 exons are 
common to all four isoforms. The divergence of isoforms starts within exon 8 where an 
alternative splice donor site results in a 53-base pair insertion unique to γ and δ 
isoforms. Inclusion of exon 8 results in a 100 base-pair insertion unique to β and γ 
isoforms. These different insertions generate reading frameshifts leading to termination 
codons and C-terminal amino acid sequences unique to each isoform. (2).  
The C-terminal tails of SH2B1 have unique motifs that affect their cellular 
localization, protein-protein interactions, and post-translational modification. SH2B1δ 
contains a unique nucleolus localization motif that resembles a basic nuclear 
localization sequence (K/R)(K/R)X(K/R) and a tryptophan-rich region but the function of 
SH2B1δ has yet to be determined.  The C-terminal tail of SH2B1β contains an actin 
binding site that facilitates cross-linking of actin filaments and is necessary for growth 
hormone-induced cellular ruffling (103). The C-terminal tails of SH2B1β and α each 
contain a single tyrosine residue, but their ability to be phosphorylated remains unclear. 
The SH2B1α C-terminal tail also contains a potential PDZ domain, S754-F-V(104,105). 
In addition, Tyr753 in SH2B1α is located within a potential phosphotyrosine-binding 
motif, N-X-X-Y, which resembles N-P-X-Y motifs that recruit adapter signaling proteins 
like Shc (106). The C-terminal Tyr753 in SH2B1α is in a motif similar to that surrounding 
the equivalent tyrosine in other SH2B family members, Tyr618 in SH2B2 and in Tyr536 
in SH2B3. Tyr618 in SH2B2 has been shown to be a substrate for PDGF and insulin 
receptors (107-110). Tyr536 in SH2B3 is a substrate for stem cell factor the receptor 
tyrosine kinase c-Kit (111). Phosphorylation of Tyr536 has been implicated in the 
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Figure 1.4. Schematic illustrating the alternative splicing of the four SH2B1 
isoforms.  Exons are denoted by boxes.  Arrows denote where stop codons reside for 
the 4 defined isoforms. 
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impairment of proliferation of bone marrow mast cells (112). These data collectively 
suggest that phosphorylation of Tyr753 in the C-terminal tail of SH2B1α may regulate 
the function of SH2B1α through recruitment of proteins that modify signal transduction. 
Furthermore, these data suggest unique functional roles for each isoform of SH2B1, 
which would enhance proteomic diversity. 
 In this thesis, I further expand our current knowledge of the neuron-specific 
SH2B1 isoform, SH2B1α, by revealing the ability of the unique C-terminal tail to impair 
SH2B1 signal transduction pathways for NGF-mediated neurite outgrowth in PC12 cells 
and NGF-mediated gene transcription. I further reveal that TrkA can phosphorylate 
Tyr753 in SH2B1α and that mutation of Ty753 restores the ability of SH2B1α to 
enhance NGF signaling pathways as well as NGF-mediated neurite extension and gene 
expression. 
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PC12 cells as a model system for delineating cellular actions of SH2B1 in 
neurotrophic factor signaling 
 
 
The PC12 cell line has been a popular cell line to use for studying NGF signal 
transduction mechanisms leading to sympathetic neurite outgrowth. PC12 cells were 
first established in 1976 from a rat adrenal pheochromocytoma (62). PC12 cells 
respond to NGF-treatment by ceasing proliferation and differentiating into sympathetic-
like neurons (61). After ceasing proliferation, an NGF-mediated signaling response 
facilitates changes to the transcriptome and proteome resulting in expression of neuron-
specific proteins (113). In addition, after NGF-induced differentiation, PC12 cells 
become electrically excitable (62,114) and have been reported to form synapses with 
primary neurons from rat cerebral cortex in culture (115). These data support the use 
and relevance of PC12 cells as an effective cell line for elucidating molecular neuronal 
differentiation mechanisms.  
PC12 cells have been used to determine NGF signaling pathways, including 
those that regulate neuronal differentiation. NGF binds to the NGF-receptor, TrkA, with 
high-affinity to activate TrkA leading to, autophosphorylation on multiple tyrosines and 
recruitment of signaling molecules including members of the PI3K/Akt, PLCγ, 
Shc/Grb2/SOS/Ras/Raf/MEK/ERK, Jun N-terminal kinase, p38 kinase and atypical 
protein kinase C pathways (55,116,117). Like NGF, EGF activates the EGF receptor to 
activate ERK1 and ERK2 (118).  However, the transient activation of ERK1 and ERK2 
by EGF promotes cellular proliferation while prolonged ERK1 and ERK2 activation in 
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response to NGF promotes differentiation (119).  The difference in response between 
EGF and NGF may be due to the recruitment of different adaptor proteins to the 
receptor signaling complex. Unlike activated EGF receptor, activated NGF-receptor, 
TrkA, recruits a multitude of adaptor proteins (e.g. FRS2 and Crk) to promote prolonged 
phosphorylation of ERK1 and ERK2 (120,121). These data suggest growth factors use 
similar signaling pathways for different physiological responses and that the signaling 
pathways are modified by adapter proteins like SH2B1. 
  NGF-mediated ERK phosphorylation occurs through multiple NGF pathways that 
synergize to maximize the cellular response. Shc adaptor protein is recruited to 
phosphoTyr490 in TrkA, activating ERK1 and ERK2 via a Shc/Grb2/SOS/Ras/Raf/MEK 
pathway (122). Additionally, ERK1 and ERK2 activation can be induced through NGF-
mediated phosphorylation of Tyr785 on TrkA, which recruits PLCγ (123). Activated PLCγ 
hydrolyzes phosphatidyl inositides yielding inositol tris-phosphate and diacylglycerol 
(DAG) (124) to promote PKCδ which in turn activates ERK1 and ERK2.  Determining 
how SH2B1 amplifies signal transduction cascades to promote a physiological cellular 
response from a growth factor is essential for discovering potential therapeutic targets. 
 The goal of the work in this thesis was to provide insight into how human 
mutations associated with human obesity affect cellular actions of SH2B1 (Chapter 2 
and 4) and how the unique C-terminal tails of the four isoforms affect the function of 
SH2B1 (Chapter 2 and 3).  
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Chapter 2 
 
Functional Characterization of Obesity-Associated Variants Involving the α and β 
Isoforms of Human SH2B1 
 
Abstract 
 
We have previously reported rare variants in Src homology 2 (SH2) B adaptor protein 1 
(SH2B1) in individuals with obesity, insulin resistance and maladaptive behavior.  Here, 
we identify four additional SH2B1 variants by sequencing 500 individuals with severe 
early-onset obesity. SH2B1 has four alternatively spliced isoforms. One variant (T546A) 
lies within the N-terminal region common to all isoforms. As shown for past variants in 
this region, T546A impairs SH2B1β enhancement of nerve growth factor (NGF)-induced 
neurite outgrowth and the individual with the T546A variant exhibits mild developmental 
delay. The other three variants (A663V, V695M and A723V) lie in the C-terminal tail of 
SH2B1α. SH2B1α variant carriers were hyperinsulinemic but did not exhibit the 
behavioral phenotype observed in individuals with SH2B1 variants that disrupt all 
isoforms. In in vitro assays, SH2B1α, like SH2B1β, enhances insulin- and leptin-induced 
IRS2 phosphorylation and growth hormone (GH)-induced cell motility. None of the 
variants affect SH2B1α enhancement of insulin- and leptin-induced IRS2 
phosphorylation.  However, T546A, A663V and A723V all impair the ability of SH2B1α 
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to enhance GH-induced cell motility. In contrast to SH2B1β, SH2B1α does not enhance 
NGF-induced neurite outgrowth. These studies suggest that genetic variants that disrupt 
isoforms other than SH2B1β may be functionally significant. Further studies are needed 
to understand the mechanism by which the individual isoforms regulate energy 
homeostasis and behavior.  
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Introduction 
Src homology 2 (SH2) B adaptor protein 1 (SH2B1) is a member of a family of 
scaffold proteins implicated in signaling downstream of a variety of receptor tyrosine 
kinases and cytokine receptors that bind to JAKs. These include receptors for leptin, 
insulin, growth hormone (GH), IGF-1, nerve growth factor (NGF), and brain-derived 
neurotrophic factor (BDNF) (125) .In mice, targeted deletion of Sh2b1 results in marked 
leptin resistance, increased food intake, severe obesity and insulin resistance. An 
intermediate obesity phenotype is seen in heterozygous null mice fed a high fat diet 
(18,19), suggesting that the obesity phenotype is dosage-dependent. 
Given the large number of receptor tyrosine kinases and cytokine receptor/JAK 
complexes that bind to SH2B1 (125), dissecting the molecular mechanisms by which 
SH2B1 regulates energy balance and glucose homeostasis has proved challenging. 
SH2B1 is alternatively spliced to yield four isoforms (α,β,δ,γ) that vary in length from 671 
to 756 amino acids.  All isoforms share a phenylalanine (Phe) zipper dimerization 
domain, nuclear localization sequence (NLS), nuclear export sequence (NES), 
Pleckstrin homology (PH) domain and SH2 domain but exhibit unique C-termini that 
vary in length from 40 (SH2B1β) to 125 (SH2B1α) amino acids (Figure 2.1) (2). The 
human SH2B1 isoforms have distinct expression patterns. While the β and γ isoforms 
are widely expressed, the α and δ isoforms are restricted to brain regions (6). Although 
very little is known about the physiological relevance of the different SH2B1 isoforms, 
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neuron-specific restoration of the β isoform in Sh2b1 null mice rescues the obese 
phenotype (54). 
We previously reported rare genetic variants in SH2B1 (P90H, T175N, P322S, 
F344Lfs*20) that are located in the N-terminal 631 amino acids shared by all four 
isoforms (1-631 region). Individuals carrying these variants exhibit severe early-onset 
obesity and insulin resistance, and a neurobehavioral phenotype characterized by 
delayed speech and language development, and maladaptive behavior (6). These 
variants disrupted SH2B1 cellular function in in vitro assays that measured GH-induced 
cell motility and NGF-induced neurite outgrowth. An additional SH2B1 variant 
(g.9483C/T), which affects only the beta (T656I) and gamma (P674S) isoforms, was 
also recently identified in obese subjects (17). This variant had no functional effect in 
the one assay tested (SH2B1 enhancement of leptin stimulation of STAT3 activity). 
Here we describe four additional SH2B1 variants identified by sequencing a 
further 500 unrelated severely obese individuals from the Genetics of Obesity Study 
(GOOS) cohort. We performed a series of functional studies of these new variants and 
those previously identified by us (P90H, T175N, P322S, F344Lfs*20) within the context 
of SH2B1α. There is evidence to support not only the role of rare variants in SH2B1 in 
severe obesity but also of common variants with a broader role in the regulation of body 
mass index (BMI). As such, we also studied a common coding variant (rs7498665; 
A484T) that has been strongly associated with BMI in genome wide association studies 
(7,126).  
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Materials and Methods 
SH2B1 variant analysis 
500 individuals with severe early-onset obesity (defined as a BMI sds>3; onset< 10 
years) were randomly selected from the Genetics of Obesity Study (GOOS) cohort 
study. Primers were designed to cover the coding sequence (NM015503) and splice 
junctions of SH2B1. Variant screening was performed using PCR, followed by direct 
sequencing using BigDye terminator chemistry (Applied Biosystems, UK) and analysis 
on an ABI 3730 automated sequencer (Applied Biosystems, UK).  
Methods for functional studies are similar to those described previously (6).  
Expression plasmids 
Unless designated otherwise, the cDNA encoding human SH2B1β(NM_001145812.1) 
(30) had the T484 SNP whereas the cDNA encoding human SH2B1α 
(NM_001145795.1) (30) had the A484 SNP. Standard PCR methods were used to 
subclone these cDNAs into pEGFPC2 (N-terminal GFP tag) or pCDNA3.1(+) (N-
terminal flag tag) vector. Mutagenesis was performed using QuikChange site-directed 
mutagenesis kit (Stratagene). cDNAs encoding flag-tagged rat JAK2 (127); flag-tagged 
IRS2 and GFP- and flag-tagged rat SH2B1β(NM_001048180) (6) were described 
previously.  
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Antibodies and hormones 
Anti-phosphotyrosine (P-Tyr-100, #9411) and anti-phospho-JAK2 [pY1007/1008] 
(#3776) were from Cell Signaling Technology and were used at a dilution of 1:1000.  
Anti-flag M2 (#F1804) (1:1000) was from Sigma, and anti-GFP (#11-814-460-001) 
(1:5000) was from Roche.  The secondary antibodies (anti-mouse and anti-rabbit) were 
from Dako and used at 1:2500 dilution. Recombinant human insulin was from Novo 
Nordisk; recombinant human leptin was from Calbiochem, recombinant human GH was 
a gift from Eli Lilly & Co. and mouse NGF was from BD Biosciences.  
Cell culture and transfection 
Q293A cells stably expressing the long form of the mouse leptin receptor (293LRb) (45), 
293 cells and 293T cells were transiently transfected using the polyethylenimine (PEI) 
method (Figures. 2.2A-C, 3.3A-D) or calcium phosphate (Figure. 2.2E). PC12 cells 
(stock from ATCC) were cultured and transfected as described previously (6). 
RAW264.7 cells (from J. Swanson, University of Michigan) were cultured in DMEM 
(Invitrogen) supplemented with 8% heat-inactivated fetal bovine serum (FBS) (Atlanta 
Biologicals), 1 mM L-glutamine and 1 mM antibiotic-antimycotic (Invitrogen) at 37°C in 
5% CO2. RAW264.7 cells were transiently transfected using Amaxa nucleofector 
(Lonza) using solution V and setting D32. 
Neurite outgrowth of PC12 cells 
Transiently transfected PC12 cells were plated on collagen-coated 60-mm dishes. 24 h 
post transfection, 25 ng/ml NGF in DMEM containing 2% horse serum, 1% FBS was 
added.  The GFP+ cells were visualized by fluorescence microscopy (Nikon Eclipse 
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TE200).  The percent of GFP+ cells that had neurite outgrowths >2 times the length of 
the cell body was determined. 
Cell imaging 
Transfected 293T cells plated on 35-mm, poly-d-lysine-coated glass-bottom culture 
dishes (MatTek Corp., Ashland, MA) were incubated for 6h in growth medium 
supplemented with 20nM leptomycin B (Sigma) to inhibit Crm1-dependent nuclear 
export.  Live GFP+ cells were visualized with an Olympus FluoView 500 laser scanning 
confocal microscope using a 60x water-immersion objective and FluoView version 5.0 
software. Linescan profiles were obtained using MetaVue Software (Universal Imaging, 
Sunnyvale, CA).  
GH-induced migration of RAW264.7 macrophages  
RAW264.7 cells (2 x 105 cells/well) transiently expressing GFP-tagged human SH2B1α 
WT or variant were incubated in growth medium for 24h, then in serum-free medium 
(1% BSA) overnight. Transfected cells suspended in serum-free medium were added to 
the upper chamber of a transwell (Costar) unit with 5-µm pore size; the lower chamber 
contained serum-free medium ± 500ng/ml human GH. Transwell units were incubated 
at 37°C in 5% CO2 for 18 h, fixed in methanol and air-dried. Cells in the upper chamber 
were removed with a cotton swab. Filter membranes were stained with hematoxylin and 
eosin (H&E) (1:10 dilution) each for 1 h and then washed with ddH2O. Cells that had 
migrated were counted (≥3 independent fields per condition) under a light microscope.  
Statistics 
Statistics were calculated using Prism 6.0c. 
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Study subjects   
The Genetics of Obesity Study (GOOS) cohort consists of 5000 probands with severe 
obesity (Body Mass Index Standard Deviation Score (BMI SDS) >3) before 10 years of 
age. BMI SDS values were calculated using UK reference data (128). We randomly 
selected five hundred individuals from this cohort; mean (±SD) BMI SDS was 4.5 ± 1.8. 
All studies were approved by the Anglia and Oxford multiregional ethics committee. 
Each subject, or parent (for children< 16 years), provided written informed consent (oral 
consent was obtained from the minors themselves). Clinical studies were conducted in 
accordance with the principles of the Declaration of Helsinki. In adults, overweight was 
defined as BMI 25–29.9 kg/m2, obesity as BMI > 30 kg/m2 according to WHO criteria. In 
children (<18y), we used definitions proposed by the International Obesity Task Force: 
overweight defined as >91st and obesity as >99th percentile for age-adjusted BMI.  
 
Publicly available database used to determine minor allele frequency 
The publicly available ESP6500 exome database is composed of exome data from 
several richly phenotyped cohorts, each consisting of controls and the extremes 
associated with heart, lung, or blood disorders (Exome Variant Server, NHLBI GO 
Exome Sequencing Project (ESP), Seattle, WA 
(URL:http://evs.gs.washington.edu/EVS/).  ESP6500 incudes 2203 African-Americans 
and 4300 European-Americans, totaling 6503 sample of unrelated individuals.  
Phenotype information about the individuals in this cohort is not available for release 
from EVS. 
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Results 
Identification of novel SH2B1 variants in severely obese individuals.  
We previously identified four variants in SH2B1 (P90H, T175N, P322S, 
F344Lfs*20) in individuals with severe early-onset obesity from the Genetics of Obesity 
(GOOS) cohort (6). In the present study, we sequenced SH2B1 in 500 additional 
individuals from this cohort. In addition to another individual carrying the T175N variant, 
we found three novel heterozygous variants in unrelated severely obese individuals: 
T546A (n=1), A663V (n=14) and A723V (n=1) (Table 2.1). One individual was 
homozygous for V695M. As with the previously reported variants, the T546A variant is 
present in all four SH2B1 isoforms. However, the three other variants (A663V, V695M 
and A723V) affect the unique C-terminal tail of SH2B1α (Figure 2.1). We sequenced 
SH2B1 in 28 available family members of severely obese probands (Table 2.1). A663V 
variants did not co-segregate with obesity in families in a classical Mendelian manner, 
suggesting that SH2B1 variants may predispose to obesity against a background of 
other genetic and environmental factors. There were an equal number of male and 
female mutation carriers (Table 2.1). Adult variant carriers were hyperinsulinemic (mean 
fasting plasma insulin 128 + 32 pmol/l; reference range 0-60 pmol/l), but euglycemic; 
liver function tests, lipid profiles and final height were in the normal range. The individual 
with the T546A variant had mild developmental delay (Table 2.1). However, no 
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neurobehavioral abnormalities were reported in individuals carrying the A663V, V695M 
or A723V variants. 
 
Differences in cellular signaling mediated by human SH2B1α and β isoforms.  
We next explored the molecular mechanisms by which these variants might 
disrupt SH2B1 function. We first studied the ability of human SH2B1α to mediate 
signaling in response to a number of ligands. As a point of reference, we compared 
these findings to those obtained using human SH2B1β. Both SH2B1α and SH2B1β bind 
to JAK2 and enhance JAK2 autophosphorylation to a similar degree (Figure 2.2A), 
consistent with results of Nishi et al. (30). SH2B1β is reported to bind to IRS proteins 
and promote their tyrosyl phosphorylation in response to insulin and leptin (45,48). Like 
SH2B1β, SH2B1α enhances both leptin-stimulated (Figure 2.2B) and insulin-stimulated 
(Figure 2.2C) tyrosyl phosphorylation of IRS2. Next, we sought to determine whether 
SH2B1α is involved in mediating the effects of neurotrophins such as NGF. Surprisingly, 
while SH2B1β enhances NGF-induced neurite outgrowth of PC12 cells (26), SH2B1α 
does not (Figure 2.2D). SH2B1β shuttles between the nucleus and the cytoplasm (76). 
Shuttling is thought to be necessary for SH2B1β to enhance transcription of NGF-
responsive genes such as uPAR, MMP3 and MMP10 (69,79), which are implicated in 
neurite outgrowth of PC12 cells (69). When 293T cells expressing either SH2B1α or 
SH2B1β are treated with the nuclear export inhibitor, leptomycin B, only the beta 
isoform is retained in the nucleus (Figure 2.2E). These results indicate that SH2B1α and 
SH2B1β share the ability to mediate signaling downstream of insulin, leptin and GH.   
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Table 2.1.  Variants in SH2B1 identified in severely obese individuals and the 
prevalence of these variants in the publicly available databases. 
 
Abbreviations: dbSNP (SNP database dbSNP138); MAF (minor-allele frequency), 
NHLBI (NIH Heart, Lung, Blood Institute) exomes (http://evs.gs.washington.edu/EVS/); 
N/A, not available. # denotes males. 
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Figure 2.1.  Identification of novel variants in SH2B1. A) Schematic showing the 
location of variants identified in SH2B1 identified in individuals with severe obesity. The 
novel variants identified in this study are shown in red. Variants reported previously and 
the common SNP (A484T) are shown in black. DD = dimerization domain, PH = 
Pleckstrin homology domain, SH2 = SH2 domain.  B) Sequence traces of the novel 
variants in this study. 
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Functional characterization of variants affecting SH2B1α.   
We next investigated the functional consequences of variants when expressed in 
the SH2B1α isoform. The distribution of SH2B1α between the plasma membrane and 
the cytoplasm is not altered However, only the beta isoform translocates to the nucleus 
and promotes NGF-induced neurite outgrowth.by any of the variants (Figure 2.3A). 
However, compared to SH2B1β, the intensity of SH2B1α in the plasma membrane 
relative to the cytoplasm is diminished (Figure 2.2E, 2.3A). Except for the frameshift 
mutant F344Lfs*20 that lacks the SH2 domain, none of the variants affect the ability of 
SH2B1α to enhance JAK2 autophosphorylation, or leptin- or insulin-induced tyrosyl 
phosphorylation of IRS2 (Figures 2.3B-D). As reported previously for SH2B1β (6), the 
P90H and P332S variants reduce the ability of SH2B1α to stimulate GH-induced cell 
migration. The T546A, A663V and A723V variants also reduce GH-induced cell 
migration (Figure 2.3E). T175N and V695M and the common SNP (A484T) have no 
impact. Finally, we tested the effect of the variants on SH2B1 enhancement of NGF-
induced neurite outgrowth. Like wild-type SH2B1α (Figure 2.2D), SH2B1α A663V, 
V695M and A723V do not enhance NGF-induced neurite outgrowth (data not shown). 
However, like the previously described human variants in the 1-631 region, the T546A 
variant impairs the ability of SH2B1β to enhance NGF-induced neurite outgrowth. The 
A484T SNP has no effect on SH2B1β enhancement of NGF-induced neurite outgrowth 
(Figure 2.3F). 
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Figure 2.2.  Comparison of SH2B1α and SH2B1β in vitro. A) 293 cells were 
transfected with the indicated constructs. Proteins in lysates were immunoprecipitated 
with anti-flag agarose. Immunoblotting was performed using the indicated antibodies. 
Results are representative of 3 experiments. B) 293LRb cells were transfected as shown, 
serum-starved, and then treated with 100ng/ml leptin for 5 min. Results are 
representative of 4 experiments. C) 293 cells were transfected with the indicated 
constructs, serum-starved and then stimulated with 100nM insulin for 5min. Results are 
representative of 4 experiments. D) PC12 cells were transiently transfected with the 
indicated constructs and treated with 25ng/ml NGF to induce neurite outgrowth. Results 
show the % of GFP+ cells with neurites greater than twice cell body length. Means ± 
range, n = 2 different experiments with 300 cells counted per condition per day of NGF 
treatment. *P<0.05 compared to GFP+ cells at the same time-point. Statistical 
significance was assessed using two-way ANOVA and Bonferroni's Multiple 
Comparisons post-test. E) Live 293T cells transiently expressing GFP-tagged human 
SH2B1β or SH2B1α were incubated ± leptomycin-B (LMB, 20 nM) for 4h and imaged 
using fluorescent confocal microscopy. Each image is representative of 50-60 cells 
visualized in 2 separate experiments.  Scale bar = 20µm. 
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Figure 2.3. Characterization of novel human variants in SH2B1. A) Live 293T cells 
transiently expressing GFP-tagged rat SH2B1β, human SH2B1α WT or human SH2B1α 
mutants were stained with the plasma membrane marker wheat germ agglutinin Alexa 
Fluor 594 and imaged by confocal microscopy. Green and red signal intensity across 
each cell were determined using line scan analysis (MetaVue).  The ratio of the plasma 
membrane: cytoplasmic signal intensity is shown (mean ±SEM).  * = p< 0.0001 by two-
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tailed, unpaired Student’s t-test compared to the ratio for rat SH2B1β WT, n = 13-19 
cells/condition.   B) 293 cells were transfected with the indicated constructs and 
resulting lysates subjected to immunoprecipitation with anti-flag agarose. 
Immunoblotting was performed using the indicated antibodies. Results are 
representative of 3 experiments. C) 293LRb cells were transfected as shown, serum-
starved, and treated with 100ng/ml leptin for 5 min. Results are representative of 4 
experiments. D) 293 cells were transfected with the indicated constructs, serum-starved 
and stimulated with 100nM insulin for 5min. Results are representative of 4 
experiments. E) RAW264.7 cells (2 x 105 cells/well) were transiently transfected as 
indicated.  Migration was analyzed using a transwell migration assay with or without GH 
(500 ng/ml) in the lower chamber for 18 h.  Values are normalized to the non-hGH 
treated GFP-SH2B1α cells.  Mean ± SEM from 3-10 independent experiments.  * = p< 
0.05 by one-tailed paired Student’s t-test. F) PC12 cells transiently expressing GFP, or 
GFP-tagged human SH2B1β T484, A484, or T546A, were treated with NGF (25 ng/ml) 
to induce neurite outgrowth. Results show the % of GFP+ cells with neurites greater 
than twice cell body length were counted. Means ± SEM, n = 3 different experiments 
with 300 cells counted per condition per day of NGF treatment.  * P < 0.05 compared to 
GFP cells at the same time-point. GFP-SH2B1β T546A cells exhibited a statistically 
lower (P < 0.05) number of neurite outgrowths at days 1-3 compared to GFP-SH2B1β 
A484 and T484.  Statistical significance was assessed using two-way ANOVA and 
Bonferroni's Multiple Comparisons post-test. 
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Discussion 
Here we describe the identification of four novel variants in SH2B1 that are 
present in individuals with obesity and insulin resistance. Some of the variants we found 
in severely obese individuals are also found in publicly available exomes (Table 1). 
However, as BMI and additional phenotypic information for individuals in these datasets 
are not available, the precise contribution of these variants to obesity remains to be 
established. 
These findings suggest that SH2B1 contains a spectrum of common and rare 
alleles which contribute to BMI and obesity predisposition with a broad range of 
penetrance, from low to more highly penetrant rare alleles. One variant, A663V, was 
identified in 14 severely obese individuals in the GOOS cohort as well as in many 
publicly available exomes. In cells, A663V affected the ability of SH2B1 to enhance cell 
motility in response to GH, therefore, it is possible that this variant may contribute to the 
phenotype of variant carriers. Additional genetic studies will be needed to determine 
whether this variant is significantly enriched in obese cohorts compared to controls. The 
nucleotide change that causes the A663V variant in SH2B1α also causes an amino acid 
change (R680C) in the δ isoform of SH2B1. Mutation of this residue in SH2B1δ impairs 
the ability of SH2B1δ to enhance NGF-induced neurite outgrowth (data not shown), a 
finding that requires further investigation.  
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We also studied the common coding SNP, A484T. A484T did not impact upon 
SH2B1α or SH2B1β in the functional assays employed here. This is consistent with a 
previous study (17), which was unable to demonstrate any functional consequence of 
the A484T SNP. It is possible that this SNP affects cellular functions of SH2B1 other 
than those tested or it may have subtle functional consequences that cannot be 
detected in the cell systems and assays we employed.  
We previously showed that individuals carrying heterozygous variants in the 1-
631 region of SH2B1 were hyperphagic, with a reduced final height, elevated plasma 
insulin levels that are disproportionate to the degree of obesity, and surprisingly, 
maladaptive behavior (6). Consistent with these findings, the individual carrying the 
T546A variant had a markedly elevated fasting plasma insulin of 123 pmol/l at age 6 
years and mild developmental delay. Whilst individuals carrying the A663V, V695M and 
A723V variants were hyperinsulinemic, none of them were reported to display any of the 
behavioral characteristics reported previously. Given the small number of individuals 
studied, these observations need to be replicated in additional studies. We also need to 
determine, at the mechanistic level, whether the behavioral phenotype results from 
disruption of a specific SH2B1 isoform (e.g.SH2B1β) or a function emanating from the 
1-631 region shared by all 4 isoforms. 
Three of the variants identified in this study are present within the unique C-
terminal tail of SH2B1α but not SH2B1β. A limited number of studies have compared 
the actions of the various isoforms in vitro. All four SH2B1 isoforms enhanced 
mitogenesis and cell proliferation in response to IGF-1, insulin and platelet-derived 
growth factor (PDGF) stimulation (2,129).  Stable expression of each isoform in NIH3T3 
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fibroblasts led to enhanced insulin receptor autophosphorylation and phosphorylation of 
IRS1 (130).  In 3T3-L1 cells, all four isoforms enhance insulin-stimulated glucose and 
amino acid transport, glycogen synthesis, lipogenesis, Akt activity, and p70 S6 kinase 
activity (130). In these assays, SH2B1α was as effective as, or more effective than, 
SH2B1β. Thus, it was surprising to observe the inability of SH2B1α to enhance NGF-
induced neurite outgrowth. The finding that the γ and δ isoforms of SH2B1 resemble 
SH2B1β in their ability to enhance NGF-induced neurite outgrowth (data not shown) 
suggest that the unique C-terminal tail of SH2B1α inhibits at least some functions 
mediated by the region of SH2B1 between amino acids 1-631. In contrast to its inability 
to promote NGF-induced neurite outgrowth, SH2B1α, like SH2B1β, was found to 
enhance GH-induced macrophage motility. Exactly how SH2B1 stimulates motility is not 
known.  However, one of the proline-rich regions present in all isoforms has been 
shown to bind Rac (89), a protein known to be involved in motility.  Ligand-dependent 
phosphorylation of tyrosines within SH2B1 appears to be critical for SH2B1 
enhancement of GH-dependent cell motility (92) suggesting that these phosphorylated 
tyrosines may recruit critical proteins to SH2B1 complexes. SH2B1β has also been 
shown to increase NGF-induced migration of PC12 cells in a wounding assay, perhaps 
by a protein kinase C-dependent process (131). The finding that most of the human 
variants impair the ability of SH2B1α and SH2B1β to enhance motility raises the 
possibility that regulation of the actin cytoskeleton and/or motility of cells is an important 
and vital component of SH2B1 function that plays a critical role in the ability of SH2B1 to 
regulate energy balance and the response to insulin. 
SH2B1 is among a small number of adaptor proteins that undergo 
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nucleocytoplasmic shuttling (76) although its exact role within the nucleus is not yet 
clear. Our previous studies suggest that neurite outgrowth requires nuclear SH2B1 (69). 
Human mutations such as P90H, T175N, P322S and F344Lfs*20 that reside in the 1-
631 region of SH2B1 impair both nuclear accumulation in the presence of LMB and 
enhancement of NGF-induced neurite outgrowth (6). Our finding here that SH2B1α 
neither accumulates in the nucleus nor enhances NGF-induced neurite outgrowth is 
consistent with SH2B1β enhancement of neurite outgrowth requiring nuclear SH2B1β.  
In contrast to neurite outgrowth, SH2B1β enhancement of GH-induced macrophage 
motility does not require its nuclear localization (92), a finding consistent with our 
observation here that SH2B1α retains the ability to enhance macrophage motility 
despite its inability to enter the nucleus. It is possible that the unique C-terminal tail of 
SH2B1α interferes with the region of SH2B1 that is required for nuclear localization. 
Masking of the region around the NLS in SH2B1α might explain why altering amino acid 
175, which lies near the NLS, impairs the ability of SH2B1β but not SH2B1α to enhance 
GH-induced macrophage migration.   
In summary, we have identified additional SH2B1 variants in individuals with 
obesity and that implicate SH2B1 isoforms besides SH2B1β as important for the 
regulation of body weight. Further studies will be needed to understand how the distinct 
C-terminal tails of the α, β, γ and δ isoforms influence SH2B1 function and their precise 
roles in vivo.  
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Chapter 3 
 
The C-terminal Tail of the α Isoform of SH2B1 Inhibits the Ability of SH2B1 to 
Enhance NGF Functions and Alters SH2B1 Subcellular Localization, Both by a 
Phosphorylation-Dependent Mechanism. 
 
Abstract 
 
The scaffold protein SH2B1, implicated as a major regulator of body weight, is recruited 
to the receptors of multiple cytokines and growth factors, including nerve growth factor 
(NGF).  We found that the β isoform, but not the α isoform of SH2B1, greatly enhances 
NGF-dependent neurite outgrowth of PC12 cells, leading us to ask how the unique C-
terminal tails of the α and β isoforms affect the ability of SH2B1 to regulate NGF 
function. We first compared the actions of SH2B1α and SH2B1β to those of SH2B1 1-
631, consisting of the N-terminal region of SH2B1 shared by all isoforms.  These results 
indicated that in contrast to the β tail, the α tail inhibits the ability of SH2B1 to cycle 
through the nucleus and enhance NGF-mediated neurite outgrowth, gene expression, 
phosphorylation of Akt and PLCγ and autophosphorylation of the NGF receptor TrkA.  
These functions were all restored when Tyr753 in the α tail was mutated to Phe.  We 
provide evidence that TrkA can phosphorylate Tyr753 in SH2B1α, as well as Tyr439 
and Tyr55 in both SH2B1α and SH2B1β. Finally, co-expression of SH2B1α, but not 
SH2β1α Y753F, inhibited the ability of SH2B1β to enhance neurite outgrowth.  These 
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results suggest that the C-terminal tails of SH2B1 isoforms are key determinants of their 
cellular roles, which are regulated by phosphorylation.  
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Introduction 
Proteomic complexity arising from alternative splicing has provided avenues for 
cells to optimize their response to a given stimulus. Receptors for growth factors and 
ligands are often alternatively spliced to produce optimized cellular signaling events for 
a single ligand, which enable distinct changes necessary for cellular homeostasis 
(97,132). The scaffold protein SH2B1 has the ability to interact with receptor tyrosine 
kinases via an SH2 domain to further modulate ligand signaling (4,23-26,125,133). To 
add further to the signaling complexity, SH2B1 is comprised of four isoforms (α, β, γ, δ)  
(2) that share their first 631 amino acids which contain a dimerization, pleckstrin 
homology (PH), and SH2 domain, nuclear localization and export sequences, and 
several proline-rich regions (134). Each isoform contains a unique C-terminal tail of 39-
125 amino acids due to alternative splicing involving exon skipping and/or alternative 5’ 
splice donor sites (2,3). In humans, SH2B1β and γ are ubiquitously expressed whereas 
SH2B1α and γ are expressed primarily in the brain (6).  Studies using SH2B1-/- mice 
and patients with mutations in SH2B1 implicate SH2B1 in a number of physiological and 
biological functions, including control of body weight and energy expenditure 
(6,13,17,135), cardiac hypertrophy(136), aggressive behavior and developmental delay 
(6,135), and glucose homeostasis (18). 
 The most pronounced phenotype in mice and humans lacking SH2B1 is their 
obesity and impaired regulation of energy balance. Sh2b1-/- mice are also hyperphagic, 
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leptin-resistant, and insulin-resistant and the males are aggressive (6,18,19).  In 
humans, SH2B1 has also been implicated as a potent regulator of energy balance.  
GWAS studies have identified SH2B1 as a gene associated with body weight (7,137).  
Individuals with gene deletions within chromosome 16p11.2 that include the SH2B1 
gene exhibit early-onset obesity and greater than expected insulin resistance (12,14).  
Most recently, non-synonymous mutations have been identified in individuals that 
exhibit severe early-onset childhood obesity (GOOS cohort).  These individuals also 
exhibit hyperphagia and greater than expected insulin resistance; some also appear to 
be aggressive and have learning issues (6,135).  Restoration of the ubiquitously 
expressed SH2B1β isoform to SH2B1-/- mice using the neuron-targeted enolase driver 
largely restores the lean phenotype (54), consistent with SH2B1 in neurons being 
critical to the physiological functions of SH2B1.   
SH2B1 has been implicated as an important regulator of cellular signaling for 
receptors for multiple growth factors and cytokines that are critical for the differentiation 
and/or function of various subsets of nerves. These include receptors for nerve growth 
factor (NGF), brain-derived growth factor (BDNF), glial-derived neurotrophic factor 
(GDNF), fibroblast growth factor, leptin, and insulin (3,22,26,27,37,133,138).  The 
cellular role of SH2B1 has been most studied in the context of signaling by the 
endogenous NGF receptor TrkA in PC12 cells, a cell type that sends out neurite 
outgrowths and expresses neuronal-specific genes in response to NGF (26,62,79).  In 
response to NGF, SH2B1 is recruited, via its SH2 domain, to the NGF receptor TrkA, 
which in turn appears to phosphorylate SH2B1 (25,26).  Overexpression and knock-
down studies showed that SH2B1 is required for maximal NGF-stimulated neurite 
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outgrowth and expression of a subset of NGF-sensitive genes (25,26,69,79). Live cell 
confocal microscopy of GFP-SH2B1β revealed that SH2B1β localizes primarily at the 
plasma membrane and in the cytoplasm in PC12, COS-7, 293T cells, and primary 
hippocampal neurons (78,139). However, SH2B1 has both a nuclear localization 
sequence (NLS) and nuclear export signal (NES), and mutating the NES or adding an 
inhibitor of nuclear export, leptomycin B (LMB), enables SH2B1β to accumulate in the 
nucleus (69,76), indicating that SH2B1 cycles through the nucleus.  Blocking the ability 
of SH2B1 to cycle through the nucleus also blocks the ability of SH2B1 to stimulate 
NGF-induced neurite outgrowth and gene expression, suggesting that cycling through 
the nucleus may be required for at least a subset of SH2B1 functions important for NGF 
signaling. 
The brain specific tissue expression of the α and δ isoforms of SH2B1 suggests 
that these two isoforms may play particularly important role in neurons. Curiously, 
however, while we found that the β isoform of SH2B1 potently enhances neurite 
outgrowth of PC12 cells, the α isoform had little to no effect nor did the α isoform 
appear to cycle through the nucleus (135).   These findings suggest that the α isoform 
may have different functions than the β isoform and that the unique C-terminal tail of 
SH2B1α and/or β is a potent regulator of SH2B1 function.  In this study, we wished to 
gain insight into how relatively small variations in scaffold proteins due to differential 
splicing might regulate the function of those proteins.  We first asked whether the 
unique α or β tail inhibits or promotes the actions of SH2B1, respectively.  We then 
examined how the isoform specific α and β tails might regulate the function of SH2B1 
and which steps in NGF signaling are affected.  Our results provide strong evidence that 
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the unique C-terminal tails of SH2B1 isoforms are key determinants of their cellular 
roles, which can be regulated by phosphorylation and dephosphorylation of critical 
amino acids.  
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Materials and methods 
Antibodies 
Rabbit polyclonal antibody to rat SH2B1 that recognizes all isoforms of SHB21 
(αSH2B1, 211) (kind gift of L. Rui, University of Michigan) was raised against 
glutathione S-transferase SH2B1β fusion protein and used at a dilution of 1:1000 for 
immunoblotting (IB) (45).   Mouse monoclonal antibody to Myc (αMyc) (9E10; IB 
1:2000) and rabbit polyclonal antibodies to Myc (A14; IB 1:1000; immunoprecipitation 
(IP) 1:50) or Trk (αTrk; C-14, sc-11; 1:500) were from Santa Cruz.  Mouse monoclonal 
antibodies to Akt (αAkt; 2920S; 1:2000) and Erks 1 and 2 (αErk 1/2; 4696S; 1:2000); 
rabbit monoclonal antibodies to phospho-Akt (Ser473) (αpAkt-Ser473; 4058L; 1:1000), 
phospho-TrkA (Y490) (αpTrkA-Y490; 4619S; 1:500), phospho-TrkA (Y674/5) (αpTrkA-
Y674/5; 4621P; 1:500), and phospho-TrkA (Y785) (αpTrkA-Y785; 4168S; 1:500); and 
rabbit polyclonal antibodies to doubly phosphorylated Erks 1 and 2 (Thr202/Tyr204) 
(αpErk 1/2; 9101S; 1:1000), PLCγ (αPLCγ; 2822S; 1:1000) and phospho-PLCγ (Tyr 
783) (αpPLCγ-Tyr 783; 2821S; 1:500) were from Cell Signaling.   Rabbit polyclonal 
antibody to Myc (αC-Myc (A190-105A); IP 1:400) came from Bethyl laboratories. Mouse 
monoclonal antibody to phosphotyrosine (αPY; 4G10; 1:1000) came from Millipore.  
Rabbit polyclonal antibody to GFP (αGFP; #632592; 1:2000) came from Clontech.  
IRDye800-conjugated, affinity purified anti-goat GFP (αGFP (600-132-215); IB: 
60 
 
1:20,000) came from Rockland Immunochemicals and IRDye 800- (827-11081) and 
IRDye 700- (926-32211) conjugated affinity-purified anti-mouse IgG and anti-rabbit IgG 
were from Li-cor Odyssey.  
Plasmids 
 cDNA encoding mouse SH2B1α was a kind gift of H. Riedel (2).  cDNAs encoding 
GFP- and Myc- tagged rat SH2B1β have been described previously (26). The sequence 
encoding mouse SH2B1α (AF421138) was subcloned into pEGFPC1 (Clontech) and 
Prk5 vector containing an N-terminal GFP and myc tag, respectively.  Additional 
mutations were introduced into SH2B1β or SH2B1α using Quickchange II Site-Directed 
mutagenesis kit (Stratagene, La Jolla, CA) according to the manufacturer’s protocol. 
Multiple mutation sites were introduced into SH2B1β or SH2B1α in successive steps 
using the same primer pairs as indicated in Table S1. Vectors encoding Td-tomato rat 
SH2B1β and mouse SH2B1α were generated by restriction digest of 5’ AgeI and 3’ 
BsrGI sites flanking the region encoding the respective GFP-tagged isoform and 
swapped with the Td-tomato sequence vectors encoding N-terminal tagged Td-tomato 
SH2B1 isoforms. 
Cell culture and transfection 
 PC12 cells (CRL-1721; ATCC) were plated on rat tail type I collagen (BD Biosciences) 
coated dishes and maintained at 37°C with humidified air at 5% CO2 in normal growth 
medium (RPMI-1640 medium [Life Technologies] 10% horse serum [HS; Atlanta], 5% 
fetal bovine serum [FBS; Life Technologies]). PC12 cells were transiently transfected 
using Lipofectamine LTX (Life Technologies) per manufacturer’s instructions for 24-72 
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h. PC12 cell lines stably overexpressing GFP or GFP tagged SH2B1β, SH2B1α, 
SH2B1α Y753F or SH2B1 1-631 were generated by transfecting cells with the indicated 
plasmid using Lipofectamine LTX for 72 h and then selecting in G418 medium (normal 
growth medium containing 0.5 mg/ml G418 [Cellco; Corning]) in normal growth medium 
for 5 days. Cells were expanded and maintained for 30 days. The top 60% of GFP-
positive cells were gated and sorted from non-GFP expressing cells by fluorescence-
activated cell sorting (FACs [Beckman Coulter MoFlo Astrios, University of Michigan 
Flow Cytometry Core]). Sorted cells were maintained in G418 medium. Prior to 
experimental use, PC12 cells were incubated overnight in deprivation medium (RPMI-
1640 containing 1% bovine serum albumin (BSA; Proliant Biologicals)). 
HEK293T cells were maintained at 37°C with humidified air at 5% CO2 in Dulbecco’s 
modified Eagle medium (DMEM; Life Technologies) supplemented with 1 mM L-
glutamine, 0.25 µg/ml amphotericin, 100 U/ml penicillin, 100 µg/ml streptomycin (DMEM 
culture medium), and 8% calf serum (CS; Life Technologies). HEK293T cells were 
transiently transfected using calcium phosphate precipitation (140) or polyethyleneimine 
(PEI; Polysciences Cat # 23966).  Briefly, PEI (1 µg/µL) was mixed with DNA at a 
4:1(w/v) ratio in Opti-Mem (Gibco by Life Technologies; 31985-070) and incubated for 
10 min at room temperature. Cells were used after 24 or 48 h.  
Neurite outgrowth  
PC12 cells or stably transfected PC12 cells were plated in 6-well dishes and transiently 
transfected with the indicated construct.  Cells were treated with 25 ng/ml 2.5S mouse 
NGF (BD BioSciences, 356004; or Harlan, BT.5025) in RPMI-1640 medium containing 
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2% HS and 1% FBS. GFP- or Td-tomato positive cells were visualized by fluorescence 
microscopy (20X or 40X objective, Nikon Eclipse TE200) after 1, 2, or 3 days. 100 GFP- 
or Td-tomato-positive cells were scored in three different areas of each plate for the 
presence of neurites 2 times the length of the cell body (total 300 cells per condition per 
experiment). The experiment was repeated 3 times (total 900 cells per condition). The 
percentage of cells with neurites was determined by dividing the number of cells with 
neurites by the total number of GFP-, Td-tomato, or GFP/Td-tomato positive cells 
counted.   
Immunoblotting and immunoprecipitation 
Stably transfected PC12 cells were seeded at 10x106 cells per 10-cm collagen-coated 
dish in normal growth medium.  After 24 h, cells were incubated overnight in deprivation 
medium. Cells were incubated at 37°C with NGF (25 or 100 ng/ml) as indicated, placed 
on ice and washed two times with phosphate buffered saline (10 mM NaPO4, 140 mM 
NaCl, pH 7.4; PBS) containing 1 mM Na3VO4 pH 7.3 (PBSV).  Cells were then lysed on 
ice for 10 min with ice-cold 20mM Tris, 150 mM NaCl, 1% Triton X-100, 1 mM EGTA, 1 
mM EDTA, 20 mM NaF, 1 mM Na3VO4, and protease inhibitors (1 mM 
phenylmethylsulfonyl fluoride (PMSF), 10 µg/ml aprotinin, 10 µg/ml leupeptin), pH 7.5.  
Cell lysates were centrifuged at ~15,000 x g for 10 min at 4°C and protein 
concentrations of the supernatant were determined using DC protein assay (Bio-Rad). 
Proteins were resolved by SDS-PAGE using 9%, 10%, or 5-12% gradient acrylamide 
gels. 
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Transfected HEK293T cells were maintained in normal growth medium and incubated at 
37°C, placed on ice and washed 2x with PBSV. Cells were then lysed on ice for 5-10 
min with ice-cold L-RIPA buffer (50mM Tris, 150 mM NaCl, 0.1% Triton X-100, 2 mM 
EGTA, 20 mM NaF, 1 mM Na3VO4, 1 mM PMSF, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 
pH 7.2.  Cell lysates were centrifuged at 8800 x g for 10 min at 4°C.  
For immunoprecipitation, antibodies to Myc ((αMyc; A14; 1:80) or (αMyc; C-Myc; 
1:450)) were pre-conjugated to protein A beads (Repligen) overnight at 4°C, and then 
added to cell lysates containing equal amounts of protein for 2-3 h at 4°C under 
constant rotation. Bound proteins were eluted and resolved on 9% acrylamide SDS-
PAGE gels. Proteins were transferred onto nitrocellulose (Bio-Rad) or low-fluorescence 
PVDF (Bio-Rad) membranes.  Blots were incubated with antibodies in 10 mM Tris, 150 
mM NaCl, pH 7.4 and 0.1% tween-20 containing either 3-5% BSA (or 1% chicken egg 
albumin for blots probed with αpTyr) overnight at 4°C, followed by secondary antibody 
for 1 h at room temperature. Bands were visualized using Odyssey Infrared Imaging 
System (LI-COR Biosciences) and quantified using Image Studio Lite 4.0.  
Cell imaging  
GFP or indicated GFP-SH2B1α or β was transiently expressed in HEK 293T cells 
seeded on 10mm glass-bottom dishes (MatTek) in normal growth medium. Cells were 
imaged in Ringer’s buffer (10 mM HEPES, 155 mM NaCl, 2 mM CaCl2, 5 mM KCl, 1 
mM MgCl2, 10 mM NaH2PO4 and 10 mM glucose, pH 7.2) using a 60x water-immersion 
objective on an Olympus FV500 laser scanning confocal microscope and FluoView 
version 5.0 software. A multi-line argon blue laser was used to excite GFP fluorescence 
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at 488 nm. Relative levels of GFP-SH2B1 in the plasma membrane (PM), cytoplasm, 
and nucleus were determined using line scans and MetaVue 6.0 (Universal Imaging, 
Sunnyvale, CA) from 16-bit images.  Image planes were chosen to allow maximal 
visualization of the plasma membrane and nucleus. GFP intensity was quantified using 
a 15-pixel wide linescan in MetaVue that was drawn perpendicular to the plasma or 
nuclear membrane and into the cytoplasm in Figures. 1E and 3A. Pixel intensity 
averages for each linescan in the PM, nucleus or cytoplasm were used to generate 
PM/cytoplasm or nuclear/cytoplasm ratios. To avoid bias, an individual blinded to the 
data generated line scans of the micrographs.  Cells were monitored after 4-6 h with 20 
nM Leptomycin B (LMB; Sigma), and imaged when the nuclear to cytoplasmic ratio of 
GFP–SH2B1β was ≥ 1.  Two or more individual experiments were conducted with each 
form of SH2B1 and 16-80 cells were quantified by line scan. Generally, 90% of the cells 
showed the same subcellular distribution for individual forms of GFP–SH2B1 at a 
medium expression level. The outliers were either clearly dying or dead cells, or the 
highest expressing cells in which the ratio of cytoplasmic to PM signal was abnormally 
high, presumably due to saturation of a limited number of binding sites in the PM.  
Quantitative polymerase chain reaction (qPCR)  
PC12 cells stably overexpressing GFP or the indicated GFP-SH2B1 were incubated at 
37°C in deprivation medium overnight. Cells were treated with or without 100 ng/ml 
NGF (Harlan) for 6 h.  Total RNA was extracted using Trizol (Ambion by Life 
Technologies) according to the manufacturer’s instructions and RNA quality confirmed 
by OD via Nanodrop spectrophotomer. cDNA was generated from the RNA using 
Taqman Reverse Transcription Reagent Kit (Applied Bio-Systems; N808-0234) per 
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manufacturer’s instructions. Transcript levels of Plaur, Mmp10, Mmp3, FosL1, Hprt  
(141), and Cyclophilin A (142) were determined in triplicate per gene by qPCR using the 
TaqMan kit (Invitrogen), SYBR green I (Life Technologies) and an Eppendorf Realplex2 
(using Mastercycler ® software). Cycle threshold values were normalized to the 
geometric mean of the cycle thresholds for HPRT and Cyclophilin A whose expression 
did not differ between the different cell lines or with NGF treatment (143). Results were 
then normalized to the GFP-SH2B1β with NGF treatment in Figure. 3.4.  
Statistics   
Statistics were performed using GraphPad Prism 7.01. For neurite outgrowth and 
western blot quantification, time course curves were converted to area under the curve 
(AUC).  For qPCR experiments, relative transcript expression levels were normalized to 
GFP-SH2B1β NGF-treated values. To account for large differences in experimental 
variability, data were transformed by taking the log of the relative expression.  One-way 
ANOVA with repeated measures and multiple comparison analysis with Dunnett’s post-
test (compared to GFP control cells) were used to test for statistical significance.  Data 
shows the mean ± S.E.M for three independent experiments (N=3) except for Figure. 
3.8A, in which the mean ± range is depicted (N=2). * indicates p-values ≤ 0.05, which 
were considered significant.  
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Results 
 
The unique C-terminal tail of the α isoform of SH2B1 inhibits the ability of SH2B1 
to enhance NGF-mediated neurite outgrowth and affects its subcellular 
localization.   
Previously, we showed that, unlike SH2B1β, SH2B1α does not enhance the 
ability of NGF to promote neurite outgrowth (135).  To determine whether the unique β 
tail enables SH2B1β to enhance neurite outgrowth or if the unique α tail prevents 
SH2B1α from enhancing neurite outgrowth, we truncated the C-terminus of SH2B1 at 
the site of alternative splicing, leaving only the N-terminal 631 amino acids shared by 
both isoforms (Figure. 3.1A). We transiently expressed GFP, or GFP-tagged SH2B1α, 
β, or 1-631 in PC12 cells and assessed the percentage of transfected cells exhibiting 
neurites after 1, 2 and 3 days of NGF treatment (Figure. 3.1B, 3.1C).  As reported 
previously (26,135), SH2B1β greatly enhanced, while SH2B1α had no effect on, neurite 
outgrowth.  SH2B1 1-631 enhanced neurite outgrowth to an extent similar to that seen 
with SH2B1β, suggesting that the unique C-terminal tail of SH2B1α prevents the N-
terminal 631 amino acids of SH2B1 from enhancing neurite outgrowth. Figure. 3.1D 
shows that these observed differences in SH2B1’s ability to enhance neurite outgrowth 
cannot be attributed to differences in levels of expression of the various forms of GFP-
SH2B1.   
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Figure 3.1.  SH2B1α‘s C-terminal tail regulates SH2B1’s ability to enhance NGF-
mediated neurite outgrowth and translocate to the nucleus. A) Schematic of 
SH2B1α, β and 1-631.  DD, dimerization domain (a.a. 25–85); NLS, nuclear localization 
sequence (a.a. 146–152); NES, nuclear export sequence (a.a. 224–233); PH, pleckstrin 
homology domain (a.a. 247–378); SH2 domain (a.a. 525–610); P, proline-rich domains 
(a.a. 16-24; 85-106); Y indicates tyrosine location. Different color tails represent unique 
isoform sequences. Numbers indicate a.a. in rat and mouse sequences. B)  PC12 cells 
transiently expressing GFP or GFP-tagged SH2B1β, SH2B1α, or 1-631 were incubated 
with 25 ng/ml NGF for the indicated number of days. The percentage of GFP-
expressing PC12 cells with neurite outgrowths at least twice the length of the cell body 
was determined on the indicated days. Results show means + s.e.m., n = 3 
experiments. C) Area under the curve (AUC) was determined from the data in panel B. * 
p ≤ 0.05 compared to cells expressing GFP.  D) PC12 cells transiently expressing GFP 
or the indicated GFP-SH2B1 treated with NGF (25 ng/mL) for 2 days. Proteins were 
separated by a 10% acrylamide SDS-PAGE gel and immunoblotted with αSH2B1 or αβ-
tubulin (control). Migration of Mw standards and the various GFP-SH2B1 are shown.  E) 
293T cells transiently expressing the indicated GFP-SH2B1 were treated with or without 
20 nM LMB for 6 h. Live cells were imaged by confocal microscopy. Scale bar = 20 µM. 
F, G) Plasma membrane (PM) to cytoplasmic (cyto) (F) or nuclear (nuc) to cyto (G) 
fluorescence ratios of cells treated as in Panel E were measured by linescan using 
MetaVue. Means ± s.e.m. of 47-80 cells from 3-4 independent experiments are shown.  
* p≤0.05 compared to GFP-SH2B1β. 
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Mutating the NLS in SH2B1β abrogates the ability of SH2B1β to both cycle  
through the nucleus and enhance NGF-mediated neurite outgrowth (69,76), suggesting 
that SH2B1 might need to enter the nucleus to promote neurite outgrowth.  Since the α 
tail prevents SH2B1α from enhancing NGF-induced neurite outgrowth, we next 
examined whether the α tail also prevents SH2B1α from cycling through the nucleus.  
Using live cell confocal microscopy, we visualized and quantified the subcellular 
localization of transiently expressed GFP tagged SH2B1α, β and 1-631 in 293T cells 
before and after treatment with the nuclear export inhibitor leptomycin B (LMB) (Figure. 
3.1E).  As reported previously (135), in the steady state (absence of LMB), GFP-
SH2B1α and β both localize primarily at the plasma membrane and in the cytoplasm 
(Figure. 3.1F).  By preventing its export from the nucleus, LMB enables GFP-SH2B1β, 
but not SH2B1α, to accumulate in the nucleus (Figures. 3.1E, 3.1G), consistent with 
SH2B1β, but not SH2B1α, being able to cycle through the nucleus. Like GFP-SH2B1α 
and β, GFP-SH2B1 1-631 localizes primarily at the plasma membrane and in the 
cytoplasm (Figures. 3.1E, 3.1F). In the presence of LMB, SH2B1 1-631 accumulates in 
the nucleus like SH2B1β and unlike SH2B1α (Figures. 3.1E, 3.1G), consistent with the 
C-terminal tail of SH2B1α preventing SH2B1α from entering the nucleus.  
Confocal microscopy also confirmed our earlier observation (135) that SH2B1α 
localizes to the plasma membrane to a lower extent than SH2B1β and further revealed 
that SH2B1 1-631 localizes to the plasma membrane to a similar extent to that of 
SH2B1β (Figures. 3.1E, 3.1F). These results suggest that the unique C-terminal tail of 
SH2B1α interferes with the ability of the N-terminal 631 amino acids of SH2B1 to 
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localize to the plasma membrane. 
 
Mutating Tyr753 in the unique C-terminal tail of SH2B1α enables SH2B1α to 
enhance NGF-mediated neurite outgrowth and cycle through the nucleus. 
  The results shown in Figures. 3.1 raise the possibility that some function of the 
unique C-terminal tail (e.g protein-protein interaction) prevents SH2B1α from enhancing 
neurite outgrowth and cycling through the nucleus.  We therefore analyzed the amino 
acid sequence of the α tail for a functional domain.  We found that the α tail contains a 
potential PDZ binding domain (N751QYSFV) (105) not present in any of the other SH2B1 
isoforms. To gain insight into whether binding of the α tail to a PDZ domain-containing 
protein might contribute to the decreased ability of SH2B1α to enhance neurite 
outgrowth, enter the nucleus, and/or localize to the plasma membrane, we mutated key 
residues in this potential PDZ binding domain.  Mutating Ser754 to Ala (S754A) and 
Val756 to Asp (V756D) did not enable GFP-SH2B1α to enhance NGF-mediated neurite 
outgrowth to a statistically significant extent (Figures. 3.2A, 3.2B) or to accumulate in 
the nucleus of LMB treated cells (Figures. 3.3A, 3.3B). However, mutating Tyr753 to 
Phe (Y753F) enabled SH2B1α to enhance neurite outgrowth to almost the same extent 
as SH2B1β (Figures. 3.2A, 3.2B) and to accumulate in the nucleus to a significantly 
greater extent than SH2B1α, although not to the same extent as SH2B1β (Figures. 
3.3B). In contrast, mutating Tyr753 to the phosphomimetic glutamic acid (Y753E) did 
not enable SH2B1α to enhance NGF-mediated neurite outgrowth or accumulate in the 
nucleus. These observed differences in SH2B1 ability to enhance neurite outgrowth 
could not be attributed to differences in levels of expression of the various forms of  
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Figure 3.2. Mutating Tyr753 in SH2B1α’s C-terminal tail enables SH2B1α to 
enhance NGF-mediated neurite outgrowth. A) Live PC12 cells transiently expressing 
GFP or the indicated GFP-SH2B1 were treated with 25 ng/ml NGF. The percentage of 
GFP-expressing cells with neurite outgrowths at least twice the length of the cell body 
length was determined on the indicated days. B) AUC was determined from the data in 
Panel A. C) PC12 cells transiently expressing GFP or the indicated GFP-SH2B1 treated 
with NGF (25 ng/mL) for 2 days. Proteins were separated by a 10% acrylamide SDS-
PAGE gel and immunoblotted with αSH2B1 or αtubulin (control). Migration of Mw 
standards and the various GFP-SH2B1 are shown. *  p ≤ 0.05 compared to GFP 
expressing cells. 
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Figure 3.3. Tyr753 in SH2B1α regulates the ability of SH2B1α to translocate to the 
nucleus. A) 293T cells expressing GFP-SH2B1β or GFP-SH2B1α were treated with or 
without 20 nM LMB for 6 h.  Live cells were imaged by confocal microscopy. Scale bar = 
20 µM.  B, C) Nuclear (nuc) to cytoplasmic (cyto) (B) or plasma membrane (PM) to cyto 
(C) fluorescence ratios of cells treated as in Panel A were measured by linescan using 
MetaVue. Means ± s.e.m. of 16-55 cells from 2-4 independent experiments are shown. * 
p≤0.05 compared to GFP-SH2B1β. 
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GFP-SH2B1 (Figures. 3.2C).  None of the mutations (S754A, V756D, Y753F, Y753E) 
affected the plasma membrane localization of SH2B1α (Figures. 3.3C).  These data 
suggest that the C-terminal tail of SH2B1α does not block the effects of SH2B1 by 
binding directly to a PDZ-domain containing protein. Rather, phosphorylation of Tyr753 
may prevent SH2B1α from enhancing NGF-induced neurite outgrowth and entering the 
nucleus. 
 
SH2B1α’s C-terminal tail prevents it from enhancing expression of NGF-
responsive genes.  
Previous studies showed that SH2B1β enhances the expression of a subset of 
NGF responsive genes, including Plaur, Mmp3, Mmp10, and FosL1 (79). Plaur is an 
early response gene that encodes urokinase plasminogen activator receptor (UPAR).  
UPAR is located on the plasma membrane where it binds to and activates plasminogen 
activator (uPA). UPAR has been shown to be necessary for NGF-mediated neurite-
outgrowth in PC12 cells (80,86). The matrix metalloproteases MMP3 and MMP10, along 
with uPA, are critical for degradation of the extracellular matrix to promote neuronal 
axon and dendrite extension (144).  Fos-like antigen 1 (FosL1, Fra1) is a member of the 
Fos family of early-response genes (145). As seen with the neurite outgrowth assays, 
overexpression of SH2B1β and 1-631 both significantly enhanced NGF-mediated 
expression of Plaur, Mmp10, and FosL1 whereas SH2B1α had no effect (Figure. 3.4).  
Mutating Tyr753 to Phe enabled SH2B1α to enhance expression of Plaur, Mmp10, and 
FosL1.  A similar trend was seen with Mmp3, although the differences did not achieve 
statistical significance. These data provide further evidence that the α tail negatively  
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Figure 3.4.  Loss of SH2B1α’s C-terminal tail or mutation of Tyr753 in the tail 
enables SH2B1α to enhance NGF-mediated gene transcription. PC12 cells stably 
overexpressing GFP (-) or the indicated GFP-tagged SH2B1 were treated with 100 
ng/mL NGF for 6 h. mRNA was collected and levels for Plaur (A.), Mmp10 (B), FosL1 
(C), Mmp3 (D) were determined by qPCR.  Relative mRNA abundance was normalized 
to the geometric mean of the levels of Hprt and Cyclophilin A mRNA. Data were 
normalized to values obtained by GFP-SH2B1β cells treated with NGF. Means ± s.e.m. 
are shown for 3 independent experiments. mRNA levels for untreated samples are 
plotted but were usually too low to be visible on the graph. * p≤0.05 compared to GFP 
with NGF. 
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regulates the ability of the N-terminus of SH2B1 to enhance NGF-mediated functions by 
a mechanism requiring phosphorylation of Tyr753. 
 
The C-terminal tail of SH2B1α inhibits SH2B1 enhancement of NGF signaling 
pathways; mutation of Tyr753 reverses that inhibition.  
To gain insight into the mechanism by which the α tail inhibits the ability of 
SH2B1α to enhance NGF-induced neurite outgrowth and gene expression, we next 
examined the effect of the α tail on the ability of SH2B1 to affect NGF signaling 
pathways. NGF-mediated neurite outgrowth in PC12 cells is initiated by NGF binding to 
and activating the receptor tyrosine kinase TrkA (55).  The resulting auto-
phosphorylation sites in TrkA recruit signaling proteins via their SH2 and/or PTB 
domains, which initiates multiple signaling pathways including those leading to rapid 
and prolonged activation of Erk1 and Erk2, Akt, and PLCγ (55).  Our lab and others 
have previously shown that overexpression of SH2B1β in PC12 cells enhances and 
prolongs NGF-induced phosphorylation of activating amino acids in Akt (Ser473) and 
PLCγ (Tyr783) (70,146).  Enhancement of phosphorylation of activating amino acids 
(Thr202, Tyr204) of Erks 1 and 2 has been observed in some (63,146) but not all 
(69,146) studies.  Consistent with these previous results, overexpression of SH2B1β in 
PC12 cells enhanced and prolonged phosphorylation of Tyr783 in PLCγ (Figures. 3.5A, 
top panel, 3.5B) and Ser473 in Akt (Figures. 3.5A, 3rd panel, 3.5C) but did not have a 
statistically significant effect on phosphorylation of Thr202/Tyr204 in Erks 1 and 2 
(Figures. 3.5A, 5th panel, 3.5D).  In contrast, overexpression of SH2B1α had no effect  
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Figure 3.5. SH2B1’s C-terminal tails modulate NGF-dependent phosphorylation of 
NGF signaling proteins.  A) Serum-starved (15h) PC12 cells stably overexpressing 
GFP (-) or the indicated GFP-tagged SH2B1 were treated with 25 ng/mL NGF for 10 or 
60 min.  Proteins in cell lysates were separated by 5-12% acrylamide gradient SDS-
PAGE gels and immunoblotted with the indicated antibodies. The 3 SH2B1 1-631 lanes 
were run on the same gel. B) The relative signal intensities of the bands & AUC 
determined from the relative signal intensities corresponding to pPLCγ, C) pAkt, and D) 
pERK1/2 were determined and normalized to the GFP signal at 10 minutes. Means ± 
s.e.m. are shown from 3 independent experiments. Mean ± s.e.m. is shown. * p ≤ 0.05 
compared to GFP. 
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on PLCγ phosphorylation (Figures 3.5A, 3.5B) and instead inhibited NGF stimulation of 
phosphorylation of Akt (Figures 3.5A, 3.5C).  Overexpression of SH2B1 1-631 (Figure 
3.5) showed enhanced and prolonged phosphorylation of PLCγ, Akt and Erks 1 and 2 
(Figures. 3.5A-D), indicating that the α tail of SH2B1α inhibits the ability of SH2B1 to 
enhance NGF signaling. Further mutating Tyr753 to Phe in the C-terminal tail of SH2B1 
overcomes the inhibitory effect of the α tail on SH2B1 enhancement of NGF-induced 
phosphorylation of PLCγ, Akt, and Erk1/2 phosphorylation. The SH2B1 Tyr753 results 
suggest that phosphorylation of Tyr753 in the α tail prevents SH2B1 from enhancing 
NGF signaling pathways, and for some pathways (e.g. Akt, Erks1/2), may even inhibit 
them, which could contribute to the inability of SH2B1α to enhance NGF-induced 
neurite outgrowth and gene expression.  
Immunoblots of the various forms of GFP-SH2B1 stably expressed in PC12 cells 
reveal that NGF causes a broadening and an upward shift in their migration in SDS 
PAGE-gels. The upward shift in SH2B1β has been shown previously to be due primarily 
to Ser/Thr phosphorylation (64). Phosphorylation on at least some of these Ser residues 
(Ser 161, 165) appears to be important for SH2B1 to leave the plasma membrane, enter 
the nucleus and enhance both NGF-induced neurite outgrowth and gene expression 
(78).  As reported previously, GFP-SH2B1β showed a robust decrease and spread in 
migration after 10 and 60 min of NGF treatment. (Figure. 3.5A, bottom panel).  GFP-
SH2B1α also exhibited a robust but more transient decrease and spread in migration. 
Mutating Tyr753 enhanced and prolonged the NGF-dependent upward shift in GFP-
SH2B1α resulting in a banding pattern that more closely resembled the migration profile 
of GFP-SH2B1β. Surprisingly, GFP-SH2B1 1-631 showed a much more modest change 
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in migration in response to NGF than either GFP-SH2B1α or β. These data are 
consistent with the C-terminal tails of both α and β increasing the ability of SH2B1 to 
become phosphorylated on Ser/Thr in response to NGF.  Phosphorylation of Tyr753 in 
the α tail appears to accelerate dephosphorylation of at least some of those Ser/Thr 
residues.   
 
The C-terminal tail of SH2B1α inhibits SH2B1 enhancement of NGF induced 
autophosphorylation of TrkA; mutation of Tyr753 reverses that inhibition. 
 Some studies have suggested that SH2B1 isoforms, which are recruited to TrkA 
via their shared SH2 domain (25,26), are capable of activating TrkA, based on their 
ability to enhance NGF-induced phosphorylation of Tyr490 in TrkA (63).  Differences in 
the ability of the different forms of SH2B1 to enhance TrkA activity or phosphorylation of 
specific Tyr in TrkA might therefore contribute to the differences in their ability to 
enhance downstream phosphorylation of NGF signaling proteins.  We used 
phosphospecific antibodies and our stably transfected PC12 cell lines to examine the 
impact of SH2B1α, β, and 1-631 on the ability of NGF (100 ng/mL) to stimulate 
phosphorylation of Tyr490, 674/675 and 785 in TrkA after 10 and 60 min (Figure. 3.6).  
Tyrosines 674/675 are the activating tyrosines of TrkA and their phosphorylation 
correlates with TrkA activity (58).  pTyr490 recruits both Shc and FRS2, both of which 
are thought to lead to activation of Erks 1 and 2 - Shc via the Shc-Grb2-SOS-Ras-Raf-
MEK-Erk1/2 pathway and FRS2 via a Crk-C3G-Rap1-B-Raf-Erks 1/2 pathway 
(116,117).  pTyr785 recruits PLCγ which catalyzes the formation of inositol 1,4,5-
trisphosphate and diacylglycerol, leading to, among a variety of things, release of Ca+2  
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Figure 3.6.  SH2B1’s C-terminal tails modulate NGF-mediated TrkA 
phosphorylation. A, B) Serum-starved (15 h) PC12 cells stably overexpressing GFP(-) 
or the indicated GFP-tagged SH2B1 were then treated with 100 ng/mL NGF for 10 and 
60 min.  Proteins in cell lysates were separated using SDS-PAGE (9% acrylamide) and 
immunoblotted with the indicated antibodies. GFP and GFP SH2B1β lanes for panels A 
and B are aliquots of the same cell lysates. The blot is representative of 3 independent 
experiments.  
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from the endoplasmic reticulum and activation of protein kinase C (123,147).  GFP- 
SH2B1β appeared to enhance the phosphorylation of all of these Tyr residues in TrkA, 
although to variable extents (compare Figures. 3.6A and 3.6B).  In contrast, 
overexpression of SH2B1α had no impact on the phosphorylation of any of these Tyr 
residues in TrkA unless Tyr 753 in SH2B1α was mutated to Phe.  Phosphorylation of 
these Tyr in TrkA in cells expressing SH2B1 1-631 resembled that observed with in 
cells expressing SH2B1β.  These data are consistent with the α tail preventing SH2B1 
from enhancing TrkA activity and subsequent autophosphorylation of Tyr490 and 
Tyr785, unless Tyr753 in the α tail is mutated to Phe.   
 
TrkA phosphorylates multiple Tyr in SH2B1α and β, including Tyr753 in SH2B1α.   
 Since mutating Tyr753 to Phe restores the ability of SH2B1α to promote NGF-
induced neurite outgrowth and gene expression, phosphorylation of Tyr753 in the α tail 
likely inhibits the actions of SH2B1.  We have shown previously that SH2B1β is 
phosphorylated on Tyr in response to NGF (26), presumably by the NGF receptor TrkA.  
We therefore wondered whether Tyr753 is a substrate of TrkA.  To gain insight into 
whether TrkA can phosphorylate Tyr753 in SH2B1α and/or other Tyr within SH2B1α 
and β, we used site-directed mutagenesis to mutate each individual Tyr in Myc-tagged 
SH2B1α or β to Phe.  The Myc tag was used because it does not contain any tyrosine 
residues.  We then transiently co-expressed each mutated SH2B1 with TrkA in 293T 
cells, immunoprecipitated each myc-SH2B1 using αMyc and immunoblotted with αpTyr.  
Figure. 3.7C reveals that both SH2B1α and β are highly phosphorylated on Tyr when  
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Figure 3.7. TrkA phosphorylates Tyr753 in SH2B1α as well as Tyr439 and 
potentially Tyr55 in SH2B1β and SH2B1α.  293T cells transiently co-expressing 
indicated myc-tagged SH2B1 with either TrkA (Panel A) or mCherry TrkA (Panel B-D) 
were lysed and proteins immunoprecipitated with αmyc. Cell lysates and  α myc 
immunoprecipitates (IP) subjected to SDS-PAGE (9% acrylamide) and immunoblotted 
with the indicated antibodies. The blots shown are representative of 3 (Panels A, B) or 2 
(Panels C, D) independent experiments. 
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co-expressed with TrkA, but not in its absence. Mutating Tyr55 or Tyr439 causes a 
substantial reduction in levels of Tyr phosphorylation of SH2B1β (Figure. 3.7A).  
Mutating both Tyr55 and 439 abrogates Tyr phosphorylation of SH2B1β (Figure. 3.7B, 
top panel), suggesting that Tyr55 and 439 are the two main substrates of TrkA in 
SH2B1β. Immunoblotting cell lysates with Ab highly specific to pTyr439 in SH2B1 (92) 
confirmed that co-expression of SH2B1β with TrkA results in phosphorylation of Tyr439 
in SH2B1β (Figure. 3.7B, 3rd panel). Phosphorylation of Tyr439 was not appreciably 
altered by mutating Tyr55.  In the case of SH2B1α, mutating Tyr753 caused a major 
reduction in its tyrosyl phosphorylation (Figure. 3.7C). Mutation of other individual Tyr 
did not cause a reproducible reduction in Tyr phosphorylation of SH2B1α suggesting 
Tyr753 is the primary substrate of TrkA. However, SH2B1 Y753F retained some Tyr 
phosphorylation, indicating that TrkA phosphorylates additional Tyr in SH2B1α.  Since 
Tyr55 and 439 in SH2B1β appear to be phosphorylated by TrkA (Figures. 3.7A, 3.7B), 
we tested whether mutating Tyr 753, 55 and 439 in different combinations would 
prevent TrkA phosphorylation of SH2B1α (Figure. 3.7D, top panel).  Only when all three 
were mutated did we see almost total absence of Tyr phosphorylation, suggesting that 
SH2B1α is phosphorylated on Tyr55 and/or 439 in addition to Tyr753.  Immunoblotting 
cell lysates with pTyr439 Ab confirmed that co-expression of SH2B1α with TrkA results 
in phosphorylation of Tyr439 (Figure. 3.7D, 3rd panel).  Levels of phosphorylation of 
Tyr439 were not significantly affected by mutating Tyr753 or Tyr55 alone or together.  
Collectively, these data are consistent with Tyr753 in the unique C-terminal tail of 
SH2B1α being a major substrate for TrkA. Additionally, Tyr 439 and most likely Tyr55, 
both in the N-terminal region shared by all 4 known isoforms of SH2B1, appear to be 
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substrates of TrkA in both SH2B1α and β.   
 
SH2B1α inhibits SH2B1-induced neurite outgrowth of PC12 cells. 
 Dimerization of both TrkA and SH2B1 has been implicated in their function 
(30,63).  This observation, combined with our findings that the unique C-terminal tail of 
SH2B1α inhibits the ability of SH2B1 to promote NGF-induced tyrosyl phosphorylation 
of TrkA and NGF signaling pathways, led us to ask whether SH2B1α inhibits the ability 
of SH2B1β to promote neurite outgrowth.  PC12 cells stably expressing GFP, or GFP-
SH2B1β, α or α Y753F were transiently transfected with Td-tomato (Tdt) or Tdt-tagged 
SH2B1β, α or α Y753F.  NGF (25 ng/ml) was added for 2 days and neurite outgrowth 
assessed in cells stably expressing both the GFP and Tdt tags (compare Figure. 3.2A 
and 3.8).  As expected, transient overexpression of Tdt itself resulted in a profile of 
neurite outgrowth similar to that observed in the absence of Tdt (see Figure. 3.2A).  
Transient overexpression of Tdt-SH2B1β increased neurite outgrowth in cells 
expressing GFP or GFP-SH2B1α but had minimal effect on cells stably expressing 
GFP-SH2B1β or SH2B1α Y753F, suggesting that maximal SH2B1 stimulation of neurite 
outgrowth had been obtained in the latter cell types.  While overexpression of Tdt-
SH2B1α had no effect on neurite outgrowth in the PC12-GFP or PC12-GFP-SH2B1α 
cells, it inhibited neurite outgrowth in the PC12-GFP-SH2B1β and PC12-GFP-SH2B1α 
Y753F cells by about 50%.  This inhibitory effect was lost when Tyr753 in Tdt-SH2B1α 
was mutated to Phe. These results are consistent with SH2B1α competing with SH2B1β 
to bind TrkA via their shared SH2 domains.  Phosphorylation of Tyr753 in SH2B1α,  
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Figure 3.8. Tyr753 in SH2B1α regulates the ability for SH2B1β to enhance NGF-
mediated neurite outgrowth. Live PC12 cells stably expressing GFP (-) or the 
indicated GFP-SH2B1 were transiently transfected with the indicated Td-Tomato (Tdt)-
tagged SH2B1 and incubated with 25 ng/ml NGF for 2 days. The percentage of cells 
expressing both Td-Tomato and GFP neurite outgrowths at least twice the length of the 
cell body length was determined. Means and ranges from 2 independent experiments 
are shown.  
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presumably by TrkA, would be expected to inactivate SH2B1α, resulting in the inability 
of a portion of the total bound SH2B1 to enhance NGF signaling gene expression and 
neurite outgrowth.  Dephosphorylation of Tyr 753 or prevention of its phosphorylation by 
TrkA would relieve or prevent, respectively, this inhibition, allowing SH2B1α to act like 
SH2B1β to enhance NGF signaling and responses. 
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Discussion 
 
 It is becoming increasingly evident that alternative splicing plays an important 
role in increasing the diversity of cellular responses both between and within different 
tissues. In this study, we show that two different isoforms of the scaffold protein SH2B1, 
SH2B1α and SH2B1β, which differ only in their C-terminal amino acids representing 
only 15 and 6% of the total protein sequence, respectively, have profoundly different 
effects on NGF signaling.  SH2B1β enhances NGF-dependent phosphorylation of TrkA, 
Akt and PLCγ, gene expression, and neurite outgrowth of PC12 cells whereas SH2B1α 
does not.  We further provide strong evidence that the α tail inhibits the ability of the 631 
N-terminal amino acids shared by all isoforms of SH2B1 to enhance these NGF 
functions, rather than the β tail enabling them.  This is supported by the findings that 
SH2B1 1-631 is as effective, if not more so, than SH2B1β in all of these activities.  
Finally, we identify potential TrkA substrate sites within SH2B1α and β and provide 
strong evidence that phosphorylation of a single amino acid (Tyr753) in the C-terminal 
tail of SH2B1α is responsible for the inhibition of SH2B1 functions by the α tail. 
Our favored hypothesis that phosphorylation of Tyr753 inhibits the ability of 
SH2B1α to serve as a signaling protein for NGF is largely based on our finding that 
mutating Tyr753 to Ala restores the ability of SH2B1α to enhance functions of NGF.   
Further support for a regulatory role for phosphorylation of Tyr753 comes from our 
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finding that mutating Tyr753 to the phosphomimetic Glu did not restore the ability of 
SH2B1α to enhance neurite outgrowth.   Further, TrkA is capable of phosphorylating 
Tyr753 in SH2B1α.  Thus, when TrkA and SH2B1α are co-expressed in 293T cells, 
SH2B1α is highly phosphorylated on Tyr in a TrkA-dependent fashion.  The level of Tyr 
phosphorylation is greatly reduced when Tyr753 is mutated to Ala. Our finding 
suggesting that TrkA can phosphorylate Tyr753 in SH2B1α is supported by unpublished 
results mentioned, but not shown or discussed, by Qian et al. (25).  The finding that 
TrkA can highly phosphorylate Tyr753 suggests that once SH2B1α is recruited to TrkA, 
Tyr753 becomes phosphorylated, which essentially turns SH2B1α off until it can be 
dephosphorylated.  It is also possible that Tyr753 is phosphorylated by other Tyr 
kinases.  Such crosstalk would enable other ligands that bind to receptor tyrosine 
kinases to negatively modulate neurotrophic factor functions by reversibly “turning off” a 
positive regulator of those functions (ie SH2B1α).  While we think it less likely, we also 
cannot rule out the possibility that mutating Tyr753 additionally or alternatively causes a 
conformational change independent of phosphorylation that relieves the inhibitory action 
of the α tail on SH2B1 function. 
Consistent with phosphorylation of Tyr753 playing an important role in regulating 
the function of SH2B1α, the C-terminal tail of SH2B1α, including the Tyr753- containing 
motif RAINNQY753SFV is highly conserved within mammals. In addition, comparable 
tyrosines are found in the C-termini of SH2B1 family members SH2B2/APS (Tyr618) 
and SH2B3/Lnk (Tyr536). Tyr618 in SH2B2/APS has been shown to be phosphorylated 
by the insulin receptor.  PhosphoTyr618 is believed to recruit the E3-ligase c-Cbl and 
facilitate the tyrosine phosphorylation of c-Cbl by the insulin receptor, association of c-
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Cbl with Crk, and ultimately the translocation of GLUT4 glucose transporters to the 
plasma membrane (109).  In contrast to SH2B1 and SH2B2/APS, which tend to 
enhance the functions of the receptors to which they are recruited, Lnk appears to 
inhibit the functions of the receptors to which it is recruited.  In fact, in contrast to 
SH2B1β, Lnk has been shown to inhibit TrkA signaling (146).  It also inhibits functions of 
the JAK2-associated erythropoietin receptor in erythroblasts (148).   Mutation of Tyr536 
to Phe modestly impaired the ability of Lnk to inhibit erythropoietin-dependent 32D cell 
proliferation and erythroblast survival.  Interestingly, though, the same mutation 
substantially enhanced the ability of Lnk to inhibit interleukin 3-dependent proliferation 
of bone marrow mast cells (111).  Synthetic peptides corresponding to the sequences 
surrounding Tyr536 (or phosphoTyr536) were conjugated to agarose beads and 
incubated with cell lysates from lymph node lymphocytes.  Immunoblotting the proteins 
bound to the beads with phosphoTyr536 but not unphosphorylated Tyr536 revealed 
PLCγ1, Grb-2 and phosphatidyl inositol 3’-kinase (149), suggesting that ligand 
stimulates the association of PLCγ1, Grb-2 and PI3K to an LNK containing complex.   
So how might phosphorylation of Tyr753 inhibit the actions of SH2B1α? The 
presence of a potential PDZ binding motif (150) containing Tyr753 raises the possibility 
that the C-terminal tail of SH2B1α binds to a PDZ domain-containing protein that inhibits 
the actions of SH2B1 and phosphorylation of Tyr753 promotes that binding.  Arguing 
against this hypothesis is our finding that mutating other critical residues expected to 
disrupt the putative PDZ binding domain does not restore the ability of SH2B1α to 
enhance NGF signaling.  Alternatively, phosphorylation of Tyr753 might promote the 
binding of a PDZ domain-containing protein, which inhibits the actions of SH2B1.  A 
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second hypothesis stems from SH2B2/APS data.  The Tyr in SH2B2/APS homologous 
to Tyr753 in SH2B1α (Tyr618) has been shown to bind to c-Cbl (109,151), raising the 
possibility that phosphoTyr753 recruits c-Cbl or another member of the Cbl family of E3 
ligases which could promote degradation of Sh2B1α or associated TrkA.  Arguing 
against this, we have not seen decreased degradation of SH2B1α or TrkA in PC12 cells 
stably expressing SH2B1α Y753F compared to SH2B1α. Although phosphoTyr536 in 
Lnk has been proposed to recruit PLCγ1, Grb-2 and PI3K (149), it is hard to imagine 
how recruiting signaling proteins that are thought to be important for NGF-induced 
neurite outgrowth would prevent, rather than enhance, the ability of SH2B1 to augment 
NGF-dependent neurite outgrowth. 
In addition, or alternatively to facilitating or blocking interaction of SH2B1α with 
another protein, phosphorylation of Tyr573 may, through a conformational change, 
cause the α tail to block the NLS. Such an interference could help explain why SH2B1α 
appears to bind to the plasma membrane to a reduced extent compared to SH2B1β and 
also show a greatly reduced ability to cycle through the nucleus, both of which are 
thought to be important for the actions of SH2B1 to enhance NGF functions. This 
reduced binding was no longer observed when Tyr753 was mutated to Phe.  Further 
experiments are clearly required to identify whether phosphorylation or 
dephosphorylation of Tyr753 regulates the binding of the C-terminal tail of SH2B1α to 
specific proteins that interfere with SH2B1 function and/or causes a conformational 
change that interferes with SH2B1 function.  
Previously, we showed that SH2B1β is phosphorylated on Tyr 439 and 494 by 
JAK2, both in the context of a 293T overexpression system (91) and in response to GH 
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stimulation of 3T3-F442A cells (92).  Here we provide evidence that TrkA, like JAK2, is 
able to phosphorylate SH2B1β on Tyr439. We also provide evidence that the second 
major TrkA substrate is Tyr55 rather than Tyr494. Tyr55 and 439 in SH2B1α also 
appear to be TrkA substrates, although they appear to be phosphorylated to a lesser 
extent than Tyr753.  Both Tyr55 and 439 were implicated as substrates in SH2B1α and 
β because of a reduced anti-phosphotyrosine signal when they were individually 
mutated and a further reduction when both were mutated together.  Tyr439 was 
confirmed as a substrate using a Tyr439 phosphospecific antibody and Tyr55 was 
mentioned as a substrate of TrkA without documentation by Qian et al. (25).  Thus, TrkA 
and JAK2 appear to share at least one substrate site in SH2B1α and β (Tyr439) but 
differ in at least one other (Tyr55 for TrkA vs Tyr494 for JAK2), allowing for some 
shared and divergent functions.  Tyr439, along with Tyr494, has been implicated in 
SH2B1β enhancement of GH-stimulated membrane ruffling in 3T3-F442A fibroblasts 
(91) and GH-stimulated motility of RAW264.7 macrophages (92).  Thus, it is tempting to 
speculate that in response to NGF, phosphoTyr439 in SH2B1β and SH2B1α Y753F 
recruit some protein important for neuronal migration or the cytoskeletal rearrangements 
that occur during neuronal differentiation.   The function of phosphoTyr55 remains to be 
determined. 
In addition to being phosphorylated on Tyr, we have shown previously that 
SH2B1 is phosphorylated on multiple Ser/Thr (64).  Phosphosite Plus 
(http://www.phosphosite.org/homeAction.action) lists 22 different phosphoserines in 
SH2B1 isoforms that have been detected by mass spectrometry, including the 8 
phosphoserines (pSer96, 124, 126, 127, 154, 161, 453 and 613) detected by our 
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laboratory (78). Mutational analysis has implicated Ser 154, 157, 161 and/or 165, which 
are proximal to the NLS, as being important in regulating the plasma membrane and 
nuclear localization of SH2B1β (78).  Preventing phosphorylation by mutating all four of 
these Ser, or even just Ser 161 and 165, to Ala redistributes SH2B1β almost exclusively 
to the plasma membrane and prevents their cycling through the nucleus whereas 
mimicking phosphorylation by mutating the Ser to Glu causes SH2B1β to leave the 
plasma membrane and enter the nucleus.  Phosphorylation of Ser 161 and 165 has also 
been implicated in GH-induced macrophage motility, based on the finding that mutating 
Ser161 and 165 individually or together inhibits GH-dependent motility whereas 
mutating the Ser to Glu enhances basal motility to the level seen in the presence of GH 
(92).  Because of this critical role of phosphoserines, we were interested to see that 
NGF stimulates an upward shift in migration of SH2B1α and a broadening of the 
SH2B1βα band in immunoblots, similar to that seen previously with SH2B1β (64).  
Digestion with phosphatases indicated that this shift was due to Tyr and Ser/Thr 
phosphorylation.  However, the shift with SH2B1α was more transient than that seen 
with SH2B1β.  Additionally, mutation of Tyr753 restored the migration pattern to 
resemble that seen with SH2B1β.  This raises the possibility that sustained Ser/Thr 
phosphorylation of SH2B1 contributes to or is necessary for SH2B1’s stimulatory effects 
on NGF-dependent neurite outgrowth and gene expression. Presumably some of the 
Ser are constitutively phosphorylated, but clearly some are phosphorylated in response 
to NGF, as has also been reported for SH2B1β that is recruited to the PDGF receptor 
(24) or the GH-receptor-JAK2 complex (4).  The Ser/Thr kinases that are responsible for 
the extensive phosphorylation are not known. But since phosphorylation occurs very 
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soon after NGF binding, it seems possible that some of the sites are phosphorylated by 
kinases that are activated by NGF.  Indeed, Rui et al. (64) provide evidence that 
SH2B1β Is phosphorylated on multiple Ser/Thr in response to NGF by kinases within 
the MEK/ERK cascade.  It will be intriguing to find out what kinases actually 
phosphorylate the various Ser/Thr with the various isoforms of SH2B1, and how that 
phosphorylation regulates their function. 
Despite significant effort, it is still not totally clear how SH2B1β enhances NGF-
induced neurite outgrowth.  Previous work and work presented here (25,26) indicate 
that SH2B1β is recruited via its SH2 domain to phosphorylated Tyr in TrkA and is 
phosphorylated by TrkA on multiple Tyr.  Our work using phosphospecific antibodies to 
various Tyr in TrkA indicate that this binding of SH2B1β to TrkA increases the activity of 
TrkA (indicated by increased phosphorylation of the activating Tyr674/675 in TrkA), 
which appears to increase phosphorylation of other tyrosines in TrkA.  In our hands, 
SH2B1β (and SH2B1 1-631) reliably increased phosphorylation of Tyr785, which would 
be expected to recruit and activate more PLCγ (123,147).  Consistent with this, we 
found that stable expression of SH2B1β and 1-631 in PC12 cells consistently enhanced 
and prolonged phosphorylation of PLCγ.  Thus, we think it likely that one of the functions 
of SH2B1 important for its enhancement of NGF functions is to increase and prolong the 
activity of PLCγ. We found SH2B1β enhancement of phosphorylation of Tyr490 to be 
more variable, being increased in some of our studies by SH2B1β and 1-631. pTyr490 
has been shown to recruit Shc and FRS-2 proteins, both implicated in activating Erks 
1/2 by initiating the Shc/grb2/SOS/Ras/Raf/MEK pathway, and the latter by prolonging 
the activation of Rap1 (120,123,147,152).  However, consistent with the more variable 
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SH2B1β-induced increase in Tyr490 phosphorylation, we do not consistently show 
SH2B1β enhancement of phosphorylation of the activating Tyr/Thr in ERKs 1/2, leading 
us to conclude that the major of effect of SH2B1β on neurite outgrowth is unlikely to be 
mediated primarily via changes in NGF activation of this pathway.  In contrast, SH2B1α 
neither stimulated the Tyr phosphorylation of any of the tested sites in TrkA, nor did it 
stimulate the phosphorylation of Erks 1/2 or PLCγ.  However, all of these were restored 
upon mutation of Tyr753.  Similar results were seen with SH2B1 stimulation of 
phosphorylation of Ser473 in Akt, another signaling protein implicated as being critical 
for NGF-induced neurite outgrowth as well as with NGF-induced gene expression.  
Thus, SH2B1β, SH2B1 1-631, and SH2B1α Y753F robustly stimulated NGF-dependent 
expression of Plaur, Mmp10, FosL1 and Mmp3 whereas SH2B1α had no effect.  The 
discrepancy between the robust SH2B1 induced enhancement of NGF-dependent 
neurite outgrowth and gene expression and the more modest increases in 
phosphorylation of TrkA and downstream signaling pathways suggest either that there 
are some as yet to be determined signaling pathways or nuclear functions of SH2B1 
that promote these functions, or that the robust end point responses are the 
consequence of multiple small changes that result in a substantial effect on neurite 
outgrowth and gene expression.  
These data together suggest a working model in which the ability of SH2B1β, 
and inability of SH2B1α, to enhance neurite outgrowth and gene transcription starts at 
the level of the TrkA receptor.  Since SH2B1β and α share a functional SH2 domain, we 
would expect them to compete for binding to a phosphorylated Tyr in TrkA.  When 
SH2B1α binds, TrkA phosphorylates Tyr753, which by some unknown mechanism 
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inactivates SH2B1α, thereby preventing enhancement of TrkA activity by either the 
bound SH2B1α or by SH2B1β that prevents it from binding to TrkA.  Because all SH2B1 
isoforms share the same SH2 domain and SH2B1 isoforms are reported to bind to 
multiple neurotrophic factor receptors, we predict that SH2B1α would similarly compete 
with other isoforms of SH2B1 for binding to TrkA and other neurotrophic factor 
receptors, including the receptor for BDNF, TrkB. One can envision that by so doing, 
SH2B1α helps to fine tune the response to neurotrophic factors which not only help to 
form but also help to prune neuronal projections, including projections in the brain that 
regulate energy expenditure.   
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This Chapter will be submitted for publication under the title “The C-terminal Tail of the 
α Isoform of SH2B1 Inhibits the Ability of SH2B1 to Enhance NGF Functions and Alters 
SH2B1 Subcellular Localization, Both by a Phosphorylation-Dependent Mechanism” by 
Ray Joe, Anabel Flores, Joel M. Cline, Erik Clutter, Paul Vander, Lawrence S. 
Argetsinger, and Christin Carter-Su. I performed neurite outgrowth assays, confocal 
microscopy, quantification of microscopy and qPCR, NGF signaling immunoblots, TrkA 
phosphorylation of SH2B1α immunoblots, and SH2B1α, and SH2B1β neurite outgrowth 
competition assay. I generated all the figures and first draft text of the manuscript.  
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Chapter 4 
 
Effect on the Ability of SH2B1 Human Obesity-Associated Variants of SH2B1 to 
Enhance Nerve Growth Factor Functions 
 
Abstract 
The scaffold protein SH2B1 has been implicated in energy homeostasis through its 
promotion of cell signaling pathways for various cytokines and growth factors, including 
leptin, insulin, and nerve growth factor. Alternative splicing of Sh2b1 generates two 
universally expressed (β and γ) isoforms and two brain-specific (α and δ) isoforms that 
share a common N-terminus but have unique C-terminal tails that vary in amino acid 
content and length. We and others have previously reported unique variants in the 
common N-termini (P90H, T175N, R270W, P322S, F344LfsX20, T546A) and unique C-
terminal tails (α-A662V, α-V695M, α-L723V, β-T655I, and γ-P673S) of SH2B1 isoforms 
in individuals with obesity and insulin resistance. Here, we characterize three more 
novel variants (R227C, G238C, and E299G) within or near the PH domain of SH2B1 
that appear associated with human obesity and insulin resistance. These new variants 
and the recently reported variants R270W and β-T655I impaired the ability of SH2B1β 
to enhance NGF-mediated neurite outgrowth in PC12 cells. However, the γ-P673S 
variant, which is the same variant as β-T655I, had no effect on the ability of SH2B1γ to 
enhance neurite outgrowth. In addition, we have determined that the P90H and P322S 
mutations impair the ability of SH2B1β to enhance expression of the NGF-responsive 
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genes Plaur, Mmp10, and FosL1 yet do not detectably influence NGF-mediated 
phosphorylation of signaling proteins PLCγ, Akt and ERKs 1 and 2.  Lastly, variants 
specific to the SH2B1α isoform (A662V, V695M, L723V) did not positively or negatively 
influence the ability of SH2B1α Y753F to enhance NGF-mediated neurite outgrowth. 
Collectively, these data suggest that: 1) the PH domain of SH2B1 is a potential 
regulatory region of SH2B1 that is important for SH2B1 enhancement of NGF-mediated 
neurite outgrowth; 2) Obesity variants impair a subset of the transcriptome enhanced by 
SH2B1β and NGF without detectably affecting known NGF-signaling pathways; and 3) 
there exists a variant within the C-terminal tail of SH2B1β that has isoform specific 
effects on neurite outgrowth. Variants within the C-terminal tail that have isoform 
specific effects on SH2B1 enhancement of neurite outgrowth and/or human physiology 
provide further evidence of isoform-specific responses to that single ligand. Further 
analysis of its PH domain and C-terminal tails will be critical to identifying the 
physiological role of SH2B1.  
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Introduction 
 
The scaffold protein SH2B1 has been shown to promote metabolic homeostasis; 
disruption of SH2B1 promotes an imbalance in energy homeostasis resulting in severe 
obesity and insulin resistance. Individuals with chromosomal deletions spanning regions 
that include SH2B1 were found to exhibit severe obesity, hyperphagia, and insulin 
resistance disproportionate to their level of obesity. (12,13,15).  Recently, individuals 
with obesity, hyperphagia, insulin resistance, maladaptive behavior were found to have 
non-synonymous variants encoding for P90H, T175N, P322S, and T546A, which are all 
located in the region of SH2B1 common to all four known isoforms of SH2B1 (6,135). 
Additional variants encoding for A662V, V695M, and L723V, which are specific to 
SH2B1α, were found in individuals who exhibited obesity and insulin resistance. 
However, maladaptive behaviors were not observed in these latter individuals (135). 
Similar to humans with the human obesity-associated mutations in SH2B1, mice with 
targeted homozygous deletion of Sh2b1 are obese, insulin resistant, and hyperphagic. 
However, it is still not clear exactly how SH2B1 regulates energy balance (18,19).  
SH2B1 is composed of multiple domains that help mediate its effects on cell 
signaling in response to key receptor tyrosine kinases and cytokine family receptors that 
bind to Janus kinases (JAKs). These include receptors for leptin, insulin, growth 
hormone, insulin-like growth factor-1 (IGF-I), nerve growth factor (NGF), brain-derived 
neurotrophic factor, and glial-derived neurotrophic factor (125). All SH2B1 isoforms 
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share several proline-rich domains, a dimerization domain, nuclear localization 
sequence (NLS), nuclear export sequence (NES), pleckstrin homology domain (PH), 
and Src-homology 2 domain (SH2). Alternative splicing of Sh2b1 produces four unique 
isoforms(α, β, γ, and δ)  that share 631 amino acids and vary at the C-terminus (2). 
SH2B1β has the shortest tail (39 amino acids) and SH2B1α has the longest tail (125 
amino acids). These tails have been shown to partially regulate the shared N-terminus 
(103) (see Chapter 3). SH2B1β and γ are universally expressed throughout all human 
tissues and SH2B1α and δ have been detected primarily in the brain (6).  Raising the 
question of the role of SH2B1 in the brain. Targeted expression of SH2B1β in the brain 
of SH2B1-deficient mice largely restores the lean phenotype (54). SH2B1β enhances 
NGF-mediated neurite outgrowth in PC12 cells (26), and enhance BDNF-induced 
neurite length and branching in primary hippocampal and cortical neurons (27). 
However, SH2B1α is unable to enhance NGF-mediated neurite outgrowth, cell signaling 
pathways, and gene expression in PC12 cells unless a conserved Tyr753 in the C-
terminal tail is mutated (135) (see Chapter 3), suggesting that phosphorylation of 
Tyr753 inhibits the function of SH2B1α.  The human obesity mutations (P90H, T175N, 
P322S, F344LfsX20, T546A) within the N-terminus of SH2B1 shared by all four 
isoforms impair the ability of SH2B1β to enhance NGF-mediated neurite outgrowth 
(6,135). However, it is unclear exactly how these mutations impair the ability of SH2B1β 
to enhance NGF-dependent neurite outgrowth.  
In this study, we examine the ability of three novel SH2B1 mutations associated 
with human obesity, R227C, G238C, E299G, the previously identified mutation R270W 
(153), and the SH2B1 variant (g.9483C/T) that encodes for SH2B1β T655I and 
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SH2B1γ P673S (17) to enhance NGF-dependent neurite outgrowth in PC12 cells. We 
also investigated the effect of the P90H and P322S mutations on the ability of SH2B1β 
to affect NGF-dependent phosphorylation of signaling proteins (PLCγ, Akt, ERKs 1 and 
2) and expression levels of Plaur, Mmp10, Mmp3, and FosL1 genes. Lastly, because 
the Tyr753Phe mutation restores the ability of SH2B1a to enhance neurite outgrowth, 
we tested the ability of the human obesity-associated SH2B1α specific mutations to 
impair neurite outgrowth in the presence of the Tyr753Phe (Y753F) mutation. These 
results collectively suggest that the PH domain is a key component of SH2B1 isoforms 
required for enhancement of NGF-mediated neurite outgrowth. Further, based on the 
gene expression studies, the human obesity associated mutations negatively impact 
only a subset of the SH2B1β and NGF regulated genes by signaling pathways not yet 
identified.  
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Materials and methods 
Antibodies 
 Mouse monoclonal antibodies to Akt (αAkt; 2920S; 1:2000) and Erks 1 and 2 (αErk 1/2; 
4696S; 1:2000); rabbit monoclonal antibodies to phospho-Akt (Ser473) (αpAkt-Ser473; 
4058L; 1:1000); and rabbit polyclonal antibodies to doubly phosphorylated Erks 1 and 2 
(Thr202/Tyr204) (αpErk 1/2; 9101S; 1:1000), PLCγ (αPLCγ; 2822S; 1:1000) and 
phospho-PLCγ (Tyr 783) (αpPLCγ-Tyr 783; 2821S; 1:500) were from Cell Signaling.  
Rabbit polyclonal antibody to GFP (αGFP; #632592; 1:2000) came from Clontech.  
IRDye800-conjugated, affinity purified anti-goat GFP (αGFP (600-132-215); IB: 
1:20,000) came from Rockland Immunochemicals and IRDye 800- (827-11081) and 
IRDye 700- (926-32211) conjugated affinity-purified anti-mouse IgG and anti-rabbit IgG 
were from Li-cor Odyssey. 
Plasmids 
 cDNA encoding mouse SH2B1α and SH2B1γ was a kind gift of H. Riedel (2). cDNAs 
encoding GFP- rat SH2B1β have been described previously (64). The sequence 
encoding mouse SH2B1α (AF421138) and SH2B1γ (AF421139) was subcloned into 
pEGFPC1 (Clontech) containing an N-terminal GFP. Additional mutations were 
introduced into SH2B1β, SH2B1α, SH2B1γ using Quickchange II Site-Directed 
mutagenesis kit (Stratagene, La Jolla, CA) according to the manufacturer’s protocol.  
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Multiple mutation sites were introduced into SH2B1α in successive steps using the 
same primer pairs. 
Cell culture and transfection   
PC12 cells (CRL-1721; ATCC) were plated on rat tail type I collagen (BD Biosciences) 
coated dishes and maintained at 37°C with humidified air at 5% CO2 in normal growth 
medium (RPMI-1640 medium [Life Technologies], 10% horse serum [HS; Atlanta], and 
5% fetal bovine serum [FBS; Life Technologies]). PC12 cells were transiently 
transfected using Lipofectamine LTX (Life Technologies) per manufacturer’s instructions 
for 24-72 h. PC12 cell lines stably overexpressing GFP or GFP tagged SH2B1β WT, 
P90H and P322S were generated by transfecting cells with the indicated plasmid using 
Lipofectamine LTX for 72 h and then selecting in G418 medium (normal growth medium 
containing 0.5 mg/ml G418 [Cellco; Corning]) for 5 days. Cells were expanded and 
maintained for 30 days. The top 60% of GFP-positive cells were gated and sorted from 
non-GFP expressing cells by fluorescence-activated cell sorting (FACs [Beckman 
Coulter MoFlo Astrios, University of Michigan Flow Cytometry Core]). Sorted cells were 
maintained in G418 medium. Prior to experimental use, PC12 cells were incubated 
overnight in deprivation medium (RPMI-1640 containing 1% bovine serum albumin 
(BSA; Proliant Biologicals)). 
Neurite outgrowth   
Transiently or stably transfected PC12 cells were plated in 6-well dishes.  Cells were 
treated with 25 ng/ml 2.5S mouse NGF (BD BioSciences, 356004; or Harlan, BT.5025) 
in RPMI-1640 medium containing 2% HS and 1% FBS. GFP- positive cells were 
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visualized by fluorescence microscopy (20X or 40X objective, Nikon Eclipse TE200) 
after 1, 2, or 3 days. 100 GFP- positive cells were scored in three different areas of 
each plate for the presence of neurites 2 times the length of the cell body. Three 
independent experiments were performed for Figure 4.1 (300 cells per experiment for a 
total of 900 cells per condition) and Figures 4.2- 3 (200 cells per experiment for a total 
of 600 cells per condition) were counted. Two independent experiments were performed 
for Figures 4.8-4.10 (300 cells per experiment for a total of 600 cells per condition). The 
percentage of cells with neurites was determined by dividing the number of cells with 
neurites by the total number of GFP- positive cells counted.   
Immunoblotting and immunoprecipitation   
Stably transfected PC12 cells were seeded at 1.0x107 cells per 10-cm collagen-coated 
dish in normal growth medium.  After 24 h, cells were incubated overnight in deprivation 
medium. Cells were incubated at 37°C with NGF (25 or 100 ng/ml) as indicated, placed 
on ice and washed two times with phosphate buffered saline (10 mM NaPO4, 140 mM 
NaCl, pH 7.4; PBS) containing 1 mM Na3VO4 pH 7.3 (PBSV).  Cells were then lysed on 
ice for 10 min with ice-cold 20mM Tris, 150 mM NaCl, 1% Triton X-100, 1 mM EGTA, 1 
mM EDTA, 20 mM NaF, 1 mM Na3VO4, and protease inhibitors (1 mM 
phenylmethylsulfonyl fluoride (PMSF), 10 µg/ml aprotinin, 10 µg/ml leupeptin), pH 7.5.  
Cell lysates were centrifuged at ~15,000 x g for 10 min at 4°C and protein 
concentrations of the supernatant were determined using DC protein assay (Bio-Rad). 
Equal amounts of proteins were resolved by SDS-PAGE using 5-12% gradient 
acrylamide gels. 
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Quantitative polymerase chain reaction (qPCR) 
 PC12 cells stably overexpressing GFP or the indicated GFP-SH2B1 were incubated at 
37°C in deprivation medium overnight. Cells were treated with or without 100 ng/ml 
NGF (Harlan) for 6 h.  Total RNA was extracted using Trizol (Ambion by Life 
Technologies) according to the manufacturer’s instructions and RNA quality confirmed 
by OD via Nanodrop spectrophotometer. cDNA was generated from the RNA using 
Taqman Reverse Transcription Reagent Kit (Applied Bio-Systems; N808-0234) per 
manufacturer’s instructions. Transcript levels of Plaur, Mmp10, Mmp3 (79), FosL1, Hprt 
(141), and Cyclophilin A (142) were determined in triplicate per gene by qPCR using the 
TaqMan kit (Invitrogen), SYBR green I (Life Technologies) and an Eppendorf Realplex2 
(using Mastercycler ® software). Cycle threshold values were normalized to the 
geometric mean of the cycle thresholds for Hprt and Cyclophilin A whose expression did 
not differ between the different cell lines or with NGF treatment (143). Results were then 
normalized to those obtained with GFP-SH2B1β cells treated with NGF.  
Statistics   
Statistics were performed using GraphPad Prism 7.02. For neurite outgrowth and 
western blot quantification, time course curves were converted to area under the curve 
(AUC).  For qPCR experiments, relative transcript expression levels were normalized to 
GFP-SH2B1β NGF-treated values. One-way ANOVA with repeated measures and 
multiple comparison analysis with Dunnett’s post-test (compared to GFP or GFP-
SH2B1β) were used to test for statistical significance.  Data shows the mean ± S.E.M 
for three independent experiments (N=3) (Figures 4.1-6). The mean ± range is depicted 
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(N=2) (Figures 4.1(P322S), 4.7-10).  * indicates p-values ≤ 0.05, which was considered 
significant. 
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Results 
 
Newly Identified SH2B1 variants associated with human obesity impair the ability 
of SH2B1 to enhance neurite extension.  
 Several new SH2B1 variants associated with severe-early onset obesity within 
SH2B1 have been identified by our collaborator, Dr. I. Sadaf Farooqi. These include 
Gly283Cys (G238C), Arg227Cys (R227C), and Glu299Gly (E299G). Volckmar et al. 
identified a variant present in both SH2B1β (T665I) and SH2B1γ (P673S) (17). Another 
study identified SH2B1 Arg270Trp (R270W) within the maturity onset diabetes of the 
young (MODY) database (153). The T655I/P673S mutation has been tested for its 
ability to inhibit SH2B1 enhancement of leptin-mediated STAT3 signaling in 293 cells 
transiently overexpressing SH2B1, LepRb and STAT3 (17). No effect of the mutations 
was observed. The impact of the other mutations on cellular effects of SH2B1 have not 
been tested. To start to gain insight into whether any of these human obesity-associated 
mutations affects the cellular actions of SH2B1, I tested the ability of these mutations to 
impair the SH2B1β enhancement of NGF-dependent neurite outgrowth in PC12 cells. 
Three of the four mutations within or near the PH domain of SH2B1(amino acids 267-
376): G238C (Figure. 4.1), R270W (Figures 4.1), and E299G (Figure. 4.2) were shown 
to significantly impair SH2B1β enhancement of NGF-mediated neurite outgrowth in 
PC12 cells. The degree of inhibition was similar to that observed previously for the 
human obesity mutation P322S (Figures. 4.1 and 4.2) (6). The R227C mutation trended 
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Figure 4.1. Human mutations G238C and R270W impair the ability of SH2B1β to 
enhance NGF-mediated neurite outgrowth. Live PC12 cells transiently expressing 
GFP or the indicated GFP-SH2B1 were treated with 25 ng/ml NGF. The percentage of 
GFP-expressing cells with neurite outgrowths at least twice the length of the cell body 
length was determined on the second day of treatment. Means ± s.e.m. are shown for 3 
independent experiments except for P322S, which is an N=2 and mean ± range is 
depicted. * p≤0.05 compared to SH2B1β. 
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Figure 4.2. Human mutations E299G and T655I impair the ability of SH2B1β to 
enhance NGF-mediated neurite outgrowth.  Live PC12 cells transiently expressing 
GFP or the indicated GFP-SH2B1 were treated with 25 ng/ml NGF. The percentage of 
GFP-expressing cells with neurite outgrowths at least twice the length of the cell body 
length was determined on the second day of treatment. Means ± s.e.m. are shown for 3 
independent experiments. * p≤0.05 compared to SH2B1β. 
 
 
 
 
 
 
 
 
 
108 
 
toward modest impairment of SH2B1-stimulated neurite outgrowth (Figure. 4.2) but the 
effect did not reach statistical significance.  The SH2B1β C-terminal tail mutant T655I 
also impaired NGF-mediated neurite outgrowth, to a similar extent as P322S (Figure. 
4.2). Unlike T655I in SH2B1β, the shared variant in the SH2B1γ isoform, P673S, did not 
impair the ability of SH2B1γ to enhance neurite outgrowth (Figure. 4.3). Together these 
data show that multiple human obesity mutations within the PH domain of SH2B1 
functionally impair SH2B1β’s ability to enhance NGF-mediated neurite outgrowth. 
Furthermore, a single mutation shared by two isoforms can regulate the function of 
SH2B1 to different degrees depending upon the isoform.  
 
SH2B1 human obesity mutations P90H and P322S minimally affect the ability of 
SH2B1 to enhance phosphorylation of NGF signaling proteins.  
We previously reported that introducing the SH2B1 human obesity variants P90H 
and P322S into SH2B1β impaired the ability of SH2B1β to enhance NGF-mediated 
neurite outgrowth in PC12 cells (6). However, it was unclear how these mutations 
impaired SH2B1β’s ability to enhance NGF-mediated neurite outgrowth. We therefore 
investigated the effect of the P90H and P322S mutations on the ability of SH2B1 to 
affect NGF signaling pathways. NGF-dependent recruit signaling proteins via their SH2 
or PTB domains to activate multiple signaling pathways including those leading to rapid 
and prolonged activation of Erk1/2, Akt, and PLCγ (58,154).  Our lab and others have 
previously shown that overexpression of SH2B1β in PC12 cells enhances and prolongs 
NGF-induced phosphorylation of activating amino acids in Akt (Ser473) and PLCγ  
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Figure 4.3. The human mutation P673S does not impair the ability of SH2B1γ to 
enhance NGF-mediated neurite outgrowth.  Live PC12 cells transiently expressing 
GFP or the indicated GFP-SH2B1 were treated with 25 ng/ml NGF. The percentage of 
GFP-expressing cells with neurite outgrowths at least twice the length of the cell body 
length was determined on the second day of treatment. Means ± s.e.m. are shown for 3 
independent experiments. * p≤0.05 compared to SH2B1γ. 
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(Tyr783) (70,146).  Enhancement of phosphorylation of activating amino acids (Thr202, 
Tyr204) of ERK1/2 has not been observed in our studies (69,146), although others have 
reported an enhancement (63,146).  We found that overexpression of SH2B1β WT 
enhanced and prolonged phosphorylation of Tyr783 in PLCγ compared to GFP control 
cells (Figure. 4.4). The mutations P90H and P322S did not impair that enhancement. 
Overexpression of SH2B1β WT, P90H or P322S did not enhance or prolong 
phosphorylation of Ser473 in Akt (Figure. 4.5A) or of Thr202/Tyr204 in Erks 1 and 2 
(Figure. 4.6), together, these data and previously reported results (146) (see Chapter 3) 
suggest that SH2B1β reproducibly enhances and prolongs NGF-mediated 
phosphorylation of PLCγ. The introduction of the human obesity mutations to SH2B1β 
has no statistically significant impact on Erk1 and ERK2, Akt, and PLCγ 
phosphorylation, despite an effect on neurite outgrowths, suggesting SH2B1β may 
impact other or additional cellular events important for neurite outgrowth.  
Post-translational modification of SH2B1 was observed after NGF treatment at 
10 and 60 minutes as reported previously (64). The upward shift in SH2B1β has been 
shown previously to be due to primarily phosphorylation of Tyr and Ser/Thr (64).  
Phosphorylation on at least some of the Ser residues (Ser 161, 165) appears to be 
important for SH2B1 to leave the plasma membrane, enter the nucleus and enhance 
both NGF-induced neurite outgrowth and gene expression (78). Immunoblots of wild 
type SH2B1β and human obesity variants P90H and P322S stably expressed in PC12 
cells reveal that NGF (Figure 4.4A, lower panel) causes a broadening and an upward 
shift in their migration in SDS-PAGE. For GFP-SH2B1β WT, the primary band after 60 
minutes is the top of the broad band (Figure. 4.4A). The migration shift seen with  
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Figure 4.4. Human obesity mutations P90H and P322S do not impair the ability of 
SH2B1β to enhance and prolong NGF-mediated PLCγ phosphorylation.  A) Serum-
starved (15h) PC12 cells stably overexpressing GFP (-) or the indicated GFP-tagged 
SH2B1 were treated with 25 ng/mL NGF for 10 or 60 min.  Proteins in cell lysates were 
separated by 5-12% acrylamide gradient SDS-PAGE gels and immunoblotted with the 
indicated antibodies. B) The relative signal intensities of the bands corresponding to 
pPLCγ and AUC determined from the relative signal intensities were determined and 
normalized to the GFP signal at 10 minutes. Means ± s.e.m. are shown from 3 
independent experiments. * p ≤ 0.05 compared to SH2B1β WT. 
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Figure 4.5. Like SH2B1β, human obesity mutations, P90H and P322S, do not 
significantly enhance NGF-mediated Akt phosphorylation.  A) Proteins in the same 
cell lysates as in Figure 4.4 were immunoblotted with the indicated antibodies. B) The 
relative signal intensities of the bands corresponding to pAkt and AUC determined from 
the relative signal intensities were determined and normalized to the GFP signal at 10 
minutes. Means ± s.e.m. are shown from 3 independent experiments.  
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Figure 4.6. Like SH2B1β, human obesity mutations, P90H and P322S, do not 
significantly enhance NGF-mediated Erk 1 and 2 phosphorylation.   A). Proteins in 
the same cell lysates as in Figure 4.4 were immunoblotted with the indicated antibodies. 
B) The relative signal intensities of the bands corresponding to pERK1/2 &and AUC 
determined from the relative signal intensities were determined and normalized to the 
GFP signal at 10 minutes. Means ± s.e.m. are shown from 3 independent experiments.  
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SH2B1β P90H and P322S is comparable to that seen with SH2B1β WT, however, no 
primary band is evident for P90H and the primary band for P322S at 60 min migration is 
slightly higher than that seen in the absence of NGF, but lower than that seen with WT 
SH2B1β (Figure. 4.4). These data suggest that the human mutations in SH2B1β may 
dysregulate the phosphorylation of SH2B1 in response to NGF. 
 
SH2B1 human obesity mutations P90H and P322S impair the ability of SH2B1 to 
enhance the expression of NGF-responsive genes. 
Previous studies showed that SH2B1β enhances the expression of a subset of 
NGF-responsive genes, including Plaur, Mmp3, Mmp10, and FosL1 (79). Plaur is an 
early-response gene that encodes urokinase plasminogen activator receptor (UPAR).  
UPAR is located on the plasma membrane where it binds to and activates plasminogen 
activator (uPA). UPAR has been shown to be necessary for NGF-mediated neurite-
outgrowth in PC12 cells (80,86). The matrix metalloproteases MMP3 and MMP10, along 
with uPA, are critical for degradation of the extracellular matrix to promote neuronal 
axon and dendrite extension (84,85).  Fos-like antigen 1 (FosL1, Fra1) is a member of 
the Fos family of early-response genes (145).  As previously reported, stable expression 
of GFP-SH2B1β significantly enhanced expression of Plaur, Mmp10, Mmp3, and FosL1 
compared to GFP control cells after 6 hours of 100 ng/ml NGF treatment (Figure. 4.7). 
Introduction of the P322S mutation impaired SH2B1β enhancement of NGF-dependent 
expression of Plaur (Figure. 4.7A), Mmp10 (Figure. 4.7B), and FosL1 (Figure. 4.7C) but 
had no effect on the expression of Mmp3 (Figure. 4.7D). The P90H mutation impaired 
the ability of SH2B1β to stimulate NGF-induced expression of Mmp10 (Figure. 4.7B),  
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Figure 4.7.  Human obesity mutations P90H and P322S impair the ability of 
SH2B1β to enhance NGF-mediated gene transcription. PC12 cells stably 
overexpressing GFP (-) or the indicated GFP-tagged SH2B1 were treated with 100 
ng/mL NGF for 6 h. mRNA was collected and levels of Plaur (A.), Mmp10 (B), FosL1 
(C), Mmp3 (D) mRNA were determined by qPCR.  Relative mRNA abundance was 
normalized to the geometric mean of the levels of Hprt and Cyclophilin A mRNA. Data 
were normalized to values obtained by GFP-SH2B1β cells treated with NGF. Means ± 
range are shown for 2 independent experiments. mRNA levels for untreated samples 
are plotted but were usually too low to be visible on the graph.  
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but had a much more modest effect on SH2B1β enhancement of expression of Plaur 
(Figure. 4.7A) and FosL1 (Figure. 4.7C). Like P322S, P90H had no effect on SH2B1 
enhancement of expression of Mmp3 (Figure. 4.7D). Collectively, these data provide 
evidence that human obesity mutations impair the ability of SH2B1β to enhance the 
expression of at least a subset of genes (Plaur, Mmp10, Mmp3, FosL1) necessary for 
NGF-induced neurite outgrowth in PC12 cells. 
 
SH2B1α-specific mutations A662V, V695M, and L723V do not alter NGF-mediated 
neurite outgrowth.  
Previously, our laboratory showed that, unlike SH2B1β, SH2B1α does not 
enhance NGF-mediated neurite outgrowth (135). In Chapter 3, I showed that mutating 
Tyr753 in the C-terminal tail of SH2B1α enables SH2B1α to enhance NGF-mediated 
neurite outgrowth in PC12 cells to a similar degree as SH2B1β (see Chapter 3). 
However, in contrast to what we observed when mutations were introduced in SH2B1β, 
the SH2B1α A662V, V694M, and L723C mutations did not impair the ability of SH2B1α 
Y753F to enhance NGF-mediated neurite outgrowth (Figures. 4.8, 4.9, 4.10). These 
results suggest that the α-specific obesity mutations may not impair neurite outgrowth.  
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Figure 4.8. Human mutation A662V does not impair the ability of SH2B1α Y753F to 
enhance NGF-mediated neurite outgrowth. A) Live PC12 cells transiently expressing 
GFP or the indicated GFP-SH2B1 were treated with 25 ng/ml NGF. The percentage of 
GFP-expressing cells with neurite outgrowths at least twice the length of the cell body 
length was determined on the second day of treatment. B) AUC was determined from 
the data in Panel A. Means ± range are shown from 2 independent experiments. 
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Figure 4.9. Human mutation V694M does not impair the ability of SH2B1α Y753F 
to enhance NGF-mediated neurite outgrowth. A) Live PC12 cells transiently 
expressing GFP or the indicated GFP-SH2B1 were treated with 25 ng/ml NGF. The 
percentage of GFP-expressing cells with neurite outgrowths at least twice the length of 
the cell body length was determined on the second day of treatment. B) AUC was 
determined from the data in Panel A. Means ± range are shown from 2 independent 
experiments. Mouse V694a amino acid corresponds to Human V694 amino acid.  
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Figure 4.10. Human mutation L723V does not impair the ability of SH2B1α Y753F 
to enhance NGF-mediated neurite outgrowth. A) Live PC12 cells transiently 
expressing GFP or the indicated GFP-SH2B1 were treated with 25 ng/ml NGF. The 
percentage of GFP-expressing cells with neurite outgrowths at least twice the length of 
the cell body length was determined on the second day of treatment. B) AUC was 
determined from the data in Panel A. Means ± range are shown from 2 independent 
experiments. Mouse L723 amino acid corresponds to Human A723 amino acid. 
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Discussion 
In this study, we have functionally characterized several new SH2B1 human 
obesity mutations common to all SH2B1 isoforms (R227C, G238C, R270W, E299G) as 
well as some unique to SH2B1β (T655I), SH2B1γ (P673S), or SH2B1α (A662V, V695M, 
L723V) for their ability to enhance NGF-mediated neurite outgrowth. In addition, we 
subjected the mutants SH2B1β P90H and P322S to cell signaling and gene expression 
assays to further reveal how these mutations disrupt the ability of SH2B1β to enhance 
NGF-induced neurite outgrowth.   
We show that the newly identified human obesity mutations G238C and E299G 
impair the ability of SH2B1β to enhance NGF-mediated neurite outgrowth in PC12 cells 
to the same extent as the P322S mutation. The identified β-T655I mutation similarly 
impaired SH2B1β enhancement of neurite outgrowth to the same extent as P322S while 
R270W had no effect. However, the P673S mutation, which in the context of SH2B1β 
(T655I) impaired SH2B1 enhancement of neurite outgrowth, had no effect in the context 
of SH2B1γ. Collectively, most of the human mutations located in the shared N-terminal 
631 amino acids of SH2B1 have been found to impair the ability of SH2B1 to enhance 
neurite outgrowth by approximately 50%.  Most of these mutations are located within 
domains of SH2B1 that are likely to be involved in protein-protein interactions. P90H lies 
in a proline-rich region; G238C lies in the NES; R270W, E299G, P322S, F344LfsX20 
are within the PH domain; and T546A is in the SH2 domain. Weakening the interaction 
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of a scaffold protein like SH2B1 to receptor tyrosine kinases or to cytokine family 
receptor-associated JAKs or to downstream signaling proteins could introduce relatively 
minor changes to cell signal fidelity that lead to an escalation of dysfunctional 
transcriptional responses, and a pathogenic state over time. The weakening of a 
protein-protein interaction due to the introduction of a disease-associated variant has 
been observed in euchromatic histone methyltransferase-1 (EHMT1) (155). 
Identification of a novel mutation encoding P809L in the conserved TPLX motif of 
EHMT-1 is associated with Kleefstra Syndrome (KS), which more commonly arises due 
to haploinsuffiency of EHMT-1. Individuals with KS exhibit severe intellectual disability 
with absent speech, hypotonia, congenital heart defects and abnormal facial features 
(156). The P809L mutation in EHMT-1 causes modest misfolding leading to irregular 
hydrogen bonding and improper hydrogen binding with its target protein demethylated 
H3K9 (155). These data provide insight into the structural instability induced by point 
mutations in proteins and their ability to dysregulate protein-protein interactions resulting 
in a pathogenic state. Examination of how the human obesity-associated mutations in 
SH2B1 disrupt the structural integrity of SH2B1 will greatly enhance our understanding 
of SH2B1’s role in scaffolding signaling complexes.  
Human obesity-associated mutations in SH2B1 lie in or adjacent to key domains 
and motifs in SH2B1. Mutations in the SH2 domain might be expected to decrease 
SH2B1 recruitment to receptor tyrosine kinases. Indeed, the F344LfsX20 mutation 
which results in a form of SH2B1 completely lacking an SH2 domain is unable to 
stimulate NGF-induced neurite outgrowth presumably due to an inability to bind via its 
SH2 domain to the NGF receptor TrkA (6). Whether SH2B1β T546A with a point 
122 
 
mutation in the SH2 domain has reduced ability to bind to TrkA has not yet been tested. 
The human obesity mutations R270W, E299G, and P322S in SH2B1 lie in the PH 
domain of SH2B1. The function of the PH domain in SH2B1 is unknown. However, 
many PH domains in signaling proteins have been reported to recognize 
phosphoinositides in the plasma membrane (77). Further examination of how the 
SH2B1 PH domain regulates SH2B1 function and determining whether the human 
obesity-associated PH domain mutations in SH2B1 alter interactions between SH2B1 
and phosphoinositides may provide insight into the function of the PH domain in SH2B1. 
The G238C mutation in SH2B1 lies in the NES, potentially impairing the ability of 
SH2B1 to exit the nucleus. Proline-rich regions have been reported to bind to SH3 
domains in signaling proteins (157). The P90H mutation in SH2B1 is located within a 
proline-rich motif potentially implicating the P90H mutation in disrupting interactions with 
SH3 domains containing signaling proteins. These human obesity-associated mutations 
that are positioned within key motifs and domains have provided regions of interests in 
SH2B1 whose function needs to be further examined. 
The P90H and P322S mutations impair the ability of SH2B1 to alter the NGF-
mediated transcriptome and neurite outgrowth (6) despite no statistically significant 
impairments to NGF-mediated phosphorylation of signaling proteins. SH2B1β P90H and 
P322S are similar to SH2B1β WT in their ability to alter NGF-mediated phosphorylation 
of cell signaling proteins PLCγ. However, in the experiments shown in Figure. 4.5, we 
did not detect a statistically significant change in NGF-mediated Akt phosphorylation 
between GFP control and SH2B1β, even though we and others have detected an 
increase in the past (shown in Figure 3.5C). Figure 4.5, we attribute the loss of a 
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statistical significant SH2B1-induced enhancement in Akt phosphorylation to use of a 
different set of stable cell lines. However, the trend of a modest SH2B1β induced 
increase in NGF-dependent Akt phosphorylation was still observed. Despite at best 
causing small changes in cell signaling, the P90H and P322S mutations exerted 
substantial effects on the expression of NGF-responsive genes Plaur, Mmp10, and 
FosL1. SH2B1β P90H and P322S were expressed to the same extent as SH2B1β WT 
in PC12 cells, thus removing the possibility of dosage differences in our overexpression 
model (6,135) (refer to Chapter 3). Further research using the stably overexpressed 
PC12 cells to identify how the SH2B1 P90H and P322S mutations alter the 
transcriptome will shed light on how these mutations alter the transcriptome. 
The SH2B1α specific mutations A662V and A723V, but not V695M, in the C-
terminal tail have been shown previously to inhibit GH-dependent motility of RAW264.7 
macrophages (135).  However, we have not yet identified any SH2B1 function in PC12 
cells that is impaired by these mutations. Unlike SH2B1β and γ, SH2B1α does not 
enhance neurite outgrowth unless Tyr753 is mutated to Phe. However, even when 
A662, V694, and L723 are mutated in the context of SH2B1α Y753F, we saw no effect 
of the mutations on SH2B1α stimulation of NGF-induced neurite outgrowth. Thus, the 
role the SH2B1α specific mutations and the effect of SH2B1α mutations on neurons are 
not yet understood. Understanding the role of SH2B1α in neurons is important due to 
the tissue-specific expression of SH2B1α in neurons in the brain and the finding that 
individuals with α-specific mutations are obese but do not exhibit the maladaptive 
behaviors seen in individuals with mutations present in all isoforms (6,135). 
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Mutation of the TrkA substrate Tyr753 in the C-terminal tail of SH2B1α impairs 
the ability of the N-termini 1-631 amino acids to enhance phosphorylation of TrkA and 
its downstream signaling pathways (refer to Chapter 3). Co-expression of SH2B1α with 
SH2B1β reduces the capacity of SH2B1β to enhance neurite outgrowth, indicating that 
SH2B1α competes with SH2B1b and presumably SH2B1γ and δ isoforms for binding to 
neurotrophic factor receptors. This would allow for a role for SH2B1α in fine tuning 
signals for spatial and temporal control of neuronal development, since SH2B1α 
appears to prevent enhancement of neurite outgrowth by other SH2B1 isoforms when 
Tyr753 is phosphorylated, or to contribute to the enhancement when Try753 is 
unphosphorylated. This fine-tuning of a signal may also involve TrkA complexes 
recruiting the E3-ligase Cbl-b, which has been shown to inhibit NGF-induced 
neuroblastoma cell differentiation (158). The interactome data gathered by Emdal et al. 
(158), using their tet-inducible TrkA neuroblastoma cell line, SH-SY5Y-Tr-TrkA, suggest 
the possibility that SH2B adapter protein family member SH2B2 (APS) may facilitate the 
association of TrkA with Cbl-b. SH2B2 has been shown to recruit E3-ligases Cbl-b and 
C-Cbl to the phosphorylated C-terminal Tyr618 in response to insulin (109,159). Tyr753 
and Tyr618 in SH2B1α and SH2B2, respectively, share homology with one another.  
The contribution of Cbl proteins to actions of SH2B1α in response to NGF-activated 
TrkA in PC12 cells has yet to be examined. Further, whether and how the human 
obesity-associated mutations in the C-terminal tail of SH2B1α affect the function of 
SH2B1α in neurons remains to be determined. However, since at least a subset of the 
mutations appear to affect GH-stimulated cell motility of macrophages (6,135), it is 
tempting to speculate that SH2B1α and the SH2B1α specific human obesity-associated 
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mutations may affect the cytoskeleton, thereby impacting neuronal migration and 
architecture.  
Collectively, we have shown that an array of human mutations associated with 
obesity impair the ability of SH2B1 to enhance NGF-induced neurite outgrowth and 
gene transcription. Transcriptional data using cells expressing SH2B1β P90H and 
SH2B1β P322S provide the most striking example of human mutations that impair a 
function of SH2B1 thought critical for neuronal function. Further analysis of this 
transcriptional effect should provide insight into the molecular basis for how these 
mutations obstruct functions of the different isoforms of SH2B1. 
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Chapter 5 
 
Summary and Future Directions 
 
 The goal of my thesis research was to identify cellular mechanisms by which 
SH2B1 isoforms affect neurotrophic functions in neurons. Individuals with variants in 
SH2B1 located within the first 631 amino acids shared by all isoforms of SH2B1 have 
been shown to have severe-early onset childhood obesity, insulin resistance, and 
maladaptive behaviors (6,135).  Individuals with mutations specific to SH2B1α and δ 
were found to have the same phenotype except they did not exhibit maladaptive 
behaviors (135). The SH2B1α and δ isoforms are expressed almost exclusively in the 
brain (6). In addition, neuronal tissue-specific expression of SH2B1β largely restores the 
lean phenotype of SH2B1-/- mice (54). These data indicating that SH2B1 in the brain 
regulates energy balance, that certain isoforms are brain specific, and that isoform 
specific mutations are associated with human obesity suggest that it is critical to 
understand the function and role of the different SH2B1 isoforms in neurons. In further 
support of a critical role for SH2B1 in neurons, SH2B1 has been implicated in 
neurotrophin-induced neurite outgrowth of several different types of neurons (25-27). 
The Carter-Su lab had shown that the obesity mutations impair SH2B1β enhancement 
of NGF-mediated neurite outgrowth (6), yet the mechanisms by which the obesity 
mutations impair neurite outgrowth remained unclear. My studies examined how these 
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mutations impair the ability of SH2B1 to enhance NGF-mediated neurite outgrowth and 
further examined how the unique SH2B1α C-terminal tail regulates the ability of SH2B1 
to enhance NGF-mediated neurite outgrowth. Future directions should focus on 
determining how SH2B1 isoforms mediate transcriptome level changes in response to a 
neurotrophin (i.e. NGF, BDNF) and how the brain-specific isoforms modulate neuronal 
circuits that regulate feeding behavior.   
Our collaborator, I. Sadaf Farooqi (University of Cambridge), identified several 
rare mutations within SH2B1 that encode for A662V, V695M, and A723V in the C-
terminal tail of SH2B1α in individuals exhibiting severe-early onset childhood obesity, 
insulin resistance, and hyperphagia. To determine what known cellular functions of 
SH2B1α are impaired by the human mutations, we performed a series of functional 
studies that we had used previously to characterize the P90H, T175N, P322S, and 
F344LfsX20 mutations within the context of SH2B1β (6). None of the shared or α-
specific SH2B1 mutations affected the ability of SH2B1α to enhance tyrosyl 
phosphorylation of IRS2 in response to leptin or insulin in a 293T overexpression 
system, suggesting that SH2B1α mutations do not contribute to obesity by 
dysregulating SH2B1α stimulation of leptin or insulin signaling.  However, the high 
levels expression of SH2B1 and IRS2 or the use of a non-neuronal cell line could have 
masked mutation-induced changes in IRS2 phosphorylation. Lowering cDNA 
expression levels and performing leptin or insulin dose response curves may have 
improved our ability to detect subtle changes in IRS2 phosphorylation, if they existed. 
However, others have performed leptin dose response experiments in 293 cells, 
transiently co-expressing the long-form of leptin receptor and SH2B1β or γ wild-type or 
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mutations (βT655I/γP674S) and observed no effects of the mutations on SH2B1β 
enhanced changes in STAT3 response in a luciferase assay (17). This suggests that 
the SH2B1 mutations in general may affect only a subset of cellular responses that 
does not include the entire repertoire of insulin or leptin responses. We also found it 
difficult to reproducibly detect SH2B1β-mediated changes in NGF-mediated 
phosphorylation of signaling proteins (PLCγ, Akt, and ERKs 1 and 2) using stable 
expression of SH2B1β, so it is not surprising that we did not reliably detect changes in 
their phosphorylation due to the human obesity mutations (refer to Chapter 4). However, 
introduction of the mutations led to robust impairments in SH2B1β enhancement of the 
expression of the early-response genes, Plaur and FosL1. This suggests that we should 
design RNA-seq or microarray experiments to investigate how the SH2B1 human 
obesity-associated mutations alter the transcriptional landscape in response to leptin or 
insulin.   
 I have initiated experiments to determine the expression of SH2B1-dependent 
genes in leptin receptor-containing neurons using translating ribosome affinity 
purification (TRAP)-sequencing (TRAP-seq). The use of TRAP-seq provides the 
opportunity to identify the abundance of actively translating transcripts in a subset of 
cells within a heterogeneous population and reduce the transcriptional noise. Neurons 
containing the leptin receptor make up a small population of cells that are located within 
the hypothalamus. We received LepRcre mice with the cre-inducible ROSA26-L10-eGFP 
from Dr. Martin Myers (University of Michigan) and have been breeding these animals 
with SH2B1flox/flox mice from Dr. Liangyou Rui (University of Michigan) to obtain mice in 
which LepRb-expressing cells lack SH2B1 and express a GFP-tagged ribosomal L10 
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subunit (L10-eGFP). GFP immunoprecipitation will be used to purify GFP-tagged L10 
along with any ribosome-associated mRNA species from LepRb neurons, which will 
then be analyzed by RNA-seq.  This experiment should provide us with insight into 
cellular mechanisms controlling gene expression in leptin receptor neurons and specific 
transcriptome events facilitated by leptin and SH2B1.   
SH2B1β has been shown to be a novel focal adhesion protein (93) that is 
required for GH-dependent migration of macrophages (92). All SH2B1 isoforms share 
an actin binding region located between amino acids 150-200 (89,103), providing an 
opportunity for all isoforms of SH2B1 to participate in actin cytoskeleton reassembly 
necessary for motility. Here, we showed that SH2B1α enhances GH-mediated 
macrophage motility to a similar extent as SH2B1β. We assessed the ability of the 
human obesity mutations in SH2B1α to enhance GH-mediated migration and identified 
a subset of the human mutations (P90H, P322S, T546A, A663V, A723V) that inhibit 
SH2B1α enhancement of GH-mediated macrophage migration. The P90H and P322S 
mutations impaired SH2B1α enhancement of motility as previously reported for 
SH2B1β (6). The A663V and A723V variants in the α-tail region also impaired SH2B1α 
enhancement of GH-dependent macrophage motility, these data suggest that cellular 
motility may be a key phenotype affected by the human obesity mutations within 
SH2B1α and β. SH2B1β has been shown to interact with the actin regulator insulin 
receptor tyrosine kinase substrate p53 (IRSp53) to promote neurite outgrowth in 
hippocampal neurons (139). Because axons, dendrites, and growth cones are highly 
dependent on the actin cytoskeleton for shape and motility, these data suggest that 
neuron-specific SH2B1α may have an important role in actin reorganization in neurons.  
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SH2B1 is a unique scaffold in its ability to localize to numerous regions of the 
cell. I found that SH2B1β localizes at a 2:1 ratio on the plasma membrane vs the 
cytoplasm (78) which would localize it appropriately to bind to receptor tyrosine kinases 
and to regulate the actin cytoskeleton in early signaling events (78). In addition, 
SH2B1β is capable of cycling into and out of the nucleus, and impairment of SH2B1β 
import into or export out of the nucleus disrupts its ability to enhance NGF-mediated 
gene expression and neurite outgrowth (69). Unlike SH2B1β, we found SH2B1α to 
localize equally between the plasma membrane and the cytoplasm and to be unable to 
accumulate in the nucleus in the presence of LMB indicating it is unable to enter the 
nucleus. Previously, our lab reported a direct correlation between the ability to cycle in 
and out of the nucleus and the ability to enhance NGF-mediated neurite outgrowth and 
gene expression (69,76). The human obesity mutations within the context of SH2B1β 
impaired the ability of SH2B1β to localize to the nucleus in the presence of LMB (6). 
Here, I report that none of the human obesity-associated mutations within the context of 
SH2B1α alter the localization of SH2B1α on the plasma membrane. We were unable to 
determine the ability of the mutations to impede nuclear localization of SH2B1α due to 
SH2B1α’s inability to cycle in and out of the nucleus. However, the finding that mutating 
Tyr753 on SH2B1α enables SH2B1α to cycle in and out of the nucleus (see Chapter 3) 
provides an avenue to determine the ability of the mutations to dysregulate nuclear 
import and export. Preliminary data performed by the Carter-Su lab expressed GFP-
tagged SH2B1β in cultured hippocampal neurons and observed GFP positive puncta 
undergoing retrograde and anterograde trafficking through axonal outgrowth (data not 
shown). This raises the possibility that the isoforms of SH2B1 may have a role in the 
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trafficking of plasma membrane proteins to the soma or nuclear proteins to the growth 
cones. Trafficking is critical for axonal growth and guidance and dendritic branching 
(160). Future experiments determining whether SH2B1 isoforms affect the subcellular 
localization of other proteins would provide functional insights into the role of SH2B1 
motility in neurons.  
Neuronal SH2B1α does not enhance NGF-mediated neurite outgrowth but 
inhibits the ability of other SH2B1 isoforms to enhance neurite extension. Mutating 
Tyr753 to Phe in the C-terminal tail of SH2B1α enhances NGF-mediated neurite 
outgrowth in PC12 cells as shown in Chapter 3, Figure 3.2 and prevents the SH2B1α-
induced inhibition of SH2B1b enhancement of neurite outgrowth. I have found that 
introduction of the α-isoform specific subset of mutations (A662V, A695M, L723V) into 
SH2B1 Y753F do not impair the ability of SH2B1a Y753F to enhance NGF-mediated 
neurite outgrowth.  Therefore, these mutations may not affect NGF-mediated neurite 
outgrowth. However, the ability of the α-isoform specific mutations to impair neurite 
outgrowth maybe be dependent on the NGF dosage. In a dose response experiment, I 
transiently expressed GFP-tagged SH2B1β and SH2B1α in PC12 cells, serum starved 
the cells overnight, and treated the cells with 10, 25, 100, 200 ng/ml of NGF. I then 
determined the percent neurite outgrowth after 2 days of NGF treatment (Figure 5.1). 
The 25 ng/ml dose of NGF used for my other neurite outgrowth experiments turns out to 
be a saturating dose based on the inability of PC12 cells exposed to higher doses of 
NGF to produce longer neurites within 2 days. Therefore, to tease out the potentially 
small changes brought about by the human obesity mutations, I propose future  
experiments to determine whether different doses of NGF shift the dose response 
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Figure 5.1. SH2B1β enhanced neurite outgrowth response by NGF is saturated.  
Live PC12 cells transiently expressing GFP or the indicated GFP-SH2B1 were treated 
with indicated NGF dose. The percentage of GFP-expressing cells with neurite 
outgrowths at least twice the length of the cell body length was determined on the 
second day of treatment. Means ± range are shown from 2 independent experiments.  
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curve. 
We have primarily focused our neurite outgrowth studies using the neurotrophin 
NGF because PC12 cells both contain endogenous TrkA which is highly responsive to 
NGF and are amenable to assessing cellular effects of SH2B1. However, it would be 
informative to determine the role of the human obesity mutations in the context of brain 
derived neurotrophic factor (BDNF). Individuals with mutations in BDNF or TrkB have 
been shown to exhibit hyperphagia and obesity (72-74,161-163). SH2B1 has been 
shown to interact with the BDNF receptor, TrkB, and to enhance neurite outgrowths 
length (25,164). More recently, overexpression of SH2B1β was shown to promote 
neurite outgrowth and branching in cultured hippocampal neurons supplemented with 
BDNF (27). The roles of SH2B1 α, γ, and δ isoforms in BDNF signaling have not been 
studied nor has the effect of any of the human obesity-associated mutations on BDNF 
function been assessed. The human obesity mutations may be expected to have a 
bigger impact on SH2B1 regulation of BDNF than NGF signaling. Studying the effects of 
the different isoforms and the human mutations on BDNF signaling and functions may 
provide critical insight into SH2B1 regulation of neuronal function critical for energy 
balance.  
 Our current knowledge of how SH2B1 contributes to cellular signaling is based 
primarily on overexpression of the SH2B1β isoform. We have provided evidence that a 
post-translational modification on a unique C-terminal tail potentially regulates the 
shared N-terminal region (see Chapter 3). However, we are unable to determine 
definitively whether Tyr753 on SH2B1α is phosphorylated without the use of a phospho-
specific antibody to Tyr753. An antibody to phosphoTyr753 would provide valuable 
134 
 
insight into whether Tyr753 is a substrate of TrkA or TrkB or other tyrosine kinases in 
the brain. Considering that Tyr753 is located 3 amino acids away from the C-terminal 
end of SH2B1α, development of a phospho-specific antibody to Tyr753 may be difficult 
to acquire. To overcome the lack of a phospho-specific antibody to Tyr753 on SH2B1α, 
experiments using stable isotope labeling with amino acids in cell culture (SILAC) or 
isobaric tag(s) for relative and absolute quantification (iTRAQ) mass spectroscopy to 
identify SH2B1α phosphorylation sites may shed light on the phosphorylation status of 
Tyr753 in SH2B1α. These experiments should identify other proteins whose 
phosphorylation is altered by SH2B1α, SH2B1α Y753F or SH2B1α with the human 
obesity-associated mutations. These experiments should elucidate traditional and novel 
signaling pathways that are regulated by SH2B1α.  
Most of my experiments used in vitro model systems to elucidate the specific 
cellular functions of different SH2B1 isoforms and to understand how the cellular 
functions of specific isoforms are affected by human mutations identified in SH2B1. 
However, it has not been determined whether SH2B1 affects the ability to promote 
axonal projections and synapses in neurons (i.e. POMC neurons) implicated in energy 
balance in the hypothalamus. Based on our previous findings implicating SH2B1 in 
neurite outgrowth and cell motility, I predict that SH2B1 affects the neuronal projections 
from, or the number of neurons in, regions of the brain that are involved in energy 
balance. To test this, I would determine if SH2B1 regulates the number of POMC 
neurons or neuronal projections to the periventricular nucleus (PVN) of the 
hypothalamus. POMC neurons are located in the arcuate nucleus and serve a primary 
role in maintaining feeding behavior and energy homeostasis (165). Brains of Sh2b1-/- 
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animals at various ages would be perfused and processed for anti-POMC 
immunohistochemistry and the number of POMC neurons and their locations 
determined (166). I predict that the absence of SH2B1 in POMC neurons will lead to a 
decrease in the number of neurons (SH2B1-/- have smaller brains, L. Rui, University of 
Michigan, personal communication) or neuronal projections to the PVN, resulting in 
abnormal synaptogenesis and impairment of POMC neurons in regulating energy 
homeostasis. However, if there is no change in POMC neurite projections to the PVN, 
there may be an imbalance of POMC neural projections to other brain regions (i.e. 
lateral hypothalamus) which could be examined.  
The results in Chapter 2 have shed light on the impact of human obesity 
mutations within the context of SH2B1α. They provided key insights into how SH2B1 C-
terminal tails have a functional role in the regulation of SH2B1. Further insight into 
regulation by SH2B1α of neuronal motility and circuit development could lay a 
foundation for identifying how the mutations contribute toward an obese phenotype. In 
Chapter 3, I investigated why SH2B1α, unlike SH2B1β and γ, does not promote NGF-
dependent neurite outgrowth. I found that removal of the unique C-terminal tail of 
SH2B1α allows SH2B1α to enhance neurite outgrowth and to accumulate in the 
nucleus in the presence of LMB to a similar or greater extent than SH2B1β. These data 
provided evidence that the C-terminal tail regulates the N-terminus of SH2B1. The 
unique C-terminus of SH2B1β has been identified as an actin binding site (103) and the 
SH2B1δ C-terminus has the ability to localize SH2B1 to the nucleolus (167), providing 
further evidence that the alternatively spliced C-terminal tails regulate the N-terminal 
631 amino acids shared by all isoforms of SH2B1. Chapter 3 also examines how the 
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SH2B1α tail attenuates the robust ability of the SH2B1 1-631 truncation mutant to 
stimulate NGF-induced neurite outgrowth.  
In Chapter 3, I present evidence that tyrosine phosphorylation of Tyr753 in the C-
terminal tail of SH2B1α inhibits the ability of the N-terminal 631 amino acids of SH2B1 
to enhance NGF-mediated phosphorylation of TrkA and cell signaling proteins (PLCγ 
and Akt), as well as expression of Plaur, Mmp10, Mmp3, and FosL1, and neurite 
outgrowth in PC12 cells. In addition, phosphorylation of Tyr753 appears to interfere with 
the ability of SH2B1α to cycle in and out of the nucleus. Tyr753 in SH2B1α is located 
within a motif, R747AXXNQY753, that is conserved between other SH2B family members, 
SH2B2/APS and SH2B3/LNK, which suggests that this Tyr may be functionally 
important. X-ray crystallography of APS has shown Tyr618 to be a key residue that 
interacts with the E3-ligase C-Cbl. In addition, amino acids R612, A613, and N616 were 
found to interact with C-Cbl (168). I mutated conserved Arg747 to an Ala (R747A) in 
SH2B1α and truncated SH2B1α prior to Arg747 (1-746) and determined the effect of 
these mutations on the ability of SH2B1α to enhance NGF-mediated neurite outgrowth 
in PC12 cells.  The 1-746 truncation enhanced neurite outgrowth to a similar extent as 
SH2B1α Y753F (Figure 5.2).  SH2B1α R747A enhanced NGF-mediated neurite 
outgrowth to a lesser extent than SH2B1α Y753F, suggesting Tyr753 is the primary 
residue responsible for SH2B1α-mediated attenuation of NGF-mediated neurite 
outgrowth (Figure 5.2).  TrkA has been shown to interact with C-Cbl, resulting in 
ubiquitination of TrkA and degradation of the complex (169). In a proteomic screen,  
Cbl-b was shown to interact with TrkA to promote TrkA ubiquitination and degradation in 
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Figure 5.2. SH2B1α 1-746 enhances NGF-mediated neurite outgrowth to a higher 
extent than R747A.  Live PC12 cells transiently expressing GFP or the indicated GFP-
SH2B1 were treated with 25 ng/ml NGF. The percentage of GFP-expressing cells with 
neurite outgrowths at least twice the length of the cell body length was determined on 
the second day of treatment. Means ± range are shown from 2 independent 
experiments.  
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the neuroblastoma cell line SH-SY5Y (158). It is unclear whether C-Cbl or Cbl-b directly 
or indirectly associates with TrkA. These data raise the possibility that the Tyr753-
containing motif may recruit C-Cbl or Cbl-b to SH2B1α, thereby bringing Cbl into close 
proximity to TrkA. Both Cbl family members have a conserved phosphotyrosine binding 
domain. Further experiments to determine whether Cbl binds to phosphorylated Y753 
on SH2B1α could provide an explanation of how SH2B1α attenuates enhanced neurite 
outgrowth. An additional functional proteomics screen may provide insight into the role 
of SH2B1 isoforms as scaffold proteins and the impact of the C-terminal tails and 
human mutations on the proteins recruited to SH2B1. 
 In addition, we tested the ability of TrkA to phosphorylate the tyrosine residues in 
SH2B1β and SH2B1α.  We determined that Tyr753 is likely to be the primary 
phosphorylation site for TrkA, and Tyr55 and Tyr439 appears to be secondary 
substrates for TrkA in 293T cells. Tyr55 and Tyr439 in SH2B1β also appear to be 
phosphorylated by TrkA. Tyr439 and Tyr494 lie in Y-X-X-L motifs and are 
phosphorylated by Jak1 and Jak2 (91). These tyrosine residues have been reported to 
be phosphorylated in response to GH in 3T3-F442A fibroblasts (92) presumably by GH-
activated Jak2. Mutating Tyr439 and 494 to Phe decreases GH-mediated motility, 
membrane ruffling and macrophage motility (91,92). However, we were unable to 
observe any decrease in phosphotyrosine levels compared to wild-type SH2B1α or β 
when SH2B1α Y494 or SH2B1β Y494F were co-expressed with TrkA. Co-expression of 
SH2B1α Y55F, Y439F, or Y753F with TrkA produced migration shifts of SH2B1 in the 
immunoblots that suggested that phosphorylation of these tyrosines may regulate a 
subset of Ser/Thr residues on SH2B1α. Mutation of Ser161 and/or Ser165 to alanine in 
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SH2B1β has been shown to decrease macrophage motility (92). Together these results 
suggest that tyrosine phosphorylation of Tyr439 in SH2B1α and SH2B1β regulates cell 
motility, which leads us to speculate that phosphorylation of SH2B1α Tyr439 may aid in 
neuronal migration in the developing brain. Determining the migration of neural crest 
cells or neurons of specific regions of the brain such as the hypothalamus in SH2B1-/- 
mice and transgenic animals expressing SH2B1 isoforms would be critical to determine 
if and how SH2B1 isoforms participate in spatial placement of neurons in the developing 
brain.  Further, experiments to verify the ability of TrkA to phosphorylate Tyr753 in 
SH2B1α and Tyr55 in various SH2B1 isoforms using phosphospecific antibodies would 
verify these tyrosines as sites of phosphorylation, and help in identification of kinases 
capable of phosphorylating them.  
This thesis research has provided critical insights at the molecular and cellular 
level into the role of SH2B1α in the function of neurotrophic factors that utilize SH2B1α 
as a signaling protein. Future studies could be directed at the level of the whole animal 
to determine whether SH2B1α alters the ability of neurons involved in energy 
expenditure to make the appropriate synaptic connections. Because the human 
phenotype of patients with genetic mutations in SH2B1 includes obesity and insulin 
resistance, such insights should increase our understanding of the cellular pathways 
and functions that lead to obesity and insulin resistance. By providing valuable 
information about how seemingly relatively minor differences between isoforms can 
have a profound impact on the function of that protein, my studies also provide 
important insight into the impact of differential splicing on neuronal function. 
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